Article

# Total Synthesis of Microcystin-LF and Derivatives Thereof

Ivan Zemskov, Stefan Altaner, Daniel R. Dietrich, and Valentin Wittmann

**Just Accepted**

# Total Synthesis of Microcystin-LF and Derivatives Thereof

Ivan Zemskov,[†] Stefan Altaner,[‡] Daniel R. Dietrich,[‡] and Valentin Wittmann[†,*]

[†]Department of Chemistry and Konstanz Research School Chemical Biology (KoRS-CB),

University of Konstanz, 78457 Konstanz (Germany)

[‡]Department of Biology and Graduate School Biological Sciences (GBS), University of

Konstanz, 78457 Konstanz (Germany)

E-mail: mail@valentin-wittmann.de

1

**1a**: R = C₆H₅
(microcystin-LF)

**1b**: R = C₆D₅

**1c**: R =

**ABSTRACT:** Microcystins (MCs) are highly toxic natural products which are produced by cyanobacteria. They can be released to the water during harmful algal blooms and are a serious threat to animals and humans. Described is the total synthesis of the cyanotoxin microcystin-LF (MC-LF, **1a**) and two derivatives thereof. Deuterated derivative **1b** is of interest as an internal standard during MC quantification in biological samples by mass spectrometry and alkyne-labeled **1c** can be employed for toxin derivatization by click chemistry with an azide-containing reporter molecule or as an activity-based probe to identify interaction partners. Application of *tert*-butyl ester protecting groups for *erythro*-β-D-methylaspartic acid and γ-D-glutamic acid were key for an isomerization-free synthesis. The analytical data of synthetic MC-LF were identical to those of an authentic sample of the natural product. All derivatives **1a-c** were determined to be potent inhibitors of protein phosphatase-1 with similar activity.

## Introduction

Microcystins (MCs) are highly toxic natural products which are produced by cyanobacteria and, according to the WHO, are amongst the most dangerous water pollutants.[1] Widespread harmful algal blooms in densely populated areas, which are favored by global warming along with eutrophication of surface waters,[2] resulted in a shutdown of the public water supply for millions of people, for example in Toledo, Ohio, USA, (August 2014) and around lake Taihu in China (July 2007).[2-3] The sole analytical method for congener-specific MC detection enabling the identification and quantification of MCs is liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS).[2b,4] However, the lack of certified reference compounds limits the applicability of this method.[2b] Although research on MCs has been conducted since 1878,[5] their physiological function in cyanobacteria is still under scientific debate.[6] Consequently, the total synthesis of MCs would provide access to a yet missing variety of reference compounds as well as microcystin derivatives for structure-activity relationship studies enabling future studies into the biological roles of MCs. Furthermore, the high cytotoxicity of MCs makes this scaffold an attractive lead structure for the development of novel potent anticancer drugs.



**Figure 1.** Microcystin-LF (MC-LF) and some amino acid variations (grey) of naturally occurring congeners. The two amino acids indicated in the name (LF in the current example) denote the natural L-amino acids in positions 2 and 4. Adda = (2*S*,3*S*,4*E*,6*E*,8*S*,9*S*)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid, D-Ala = D-alanine, γ-D-Glu = γ-D-

3

glutamic acid, Mdha = *N*-methyldehydroalanine, β-D-MeAsp = *erythro*-β-D-methylaspartic acid.

As shown in Figure 1, MCs consist of three D-amino acids in positions 1, 3, and 6, the β-amino acid Adda[5], and *N*-methyldehydroalanine (Mdha[7]) which is involved in covalent binding of MCs to protein phosphatases by Michael addition of a proximate cysteine residue.[7] Two L-amino acids in positions 2 and 4 are variable and count for the major differences between the more than 100 individual congeners, that have been reported so far.[8] Despite numerous attempts[9] the total synthesis of a natural microcystin (MC-LA) was accomplished only once.[10] This landmark achievement featured protection of β-D-MeAsp[3] and γ-D-Glu[6] by methyl esters that were cleaved under basic conditions in the last synthetic step. Unfortunately, this treatment led to the formation of several uncharacterized isomers of the final product.[10] In our interpretation the isomerization can be attributed to a cyclization involving β-D-MeAsp[3] (**I**, Scheme 1) leading to aspartimide **II** which is prone to isomerization at the chiral centers in α- and β-positions. Ring opening by basic hydrolysis can lead to the stereoisomers **III** of desired MC-LA as well as constitutional isomers **IV**. Despite extensive investigation of different methyl ester cleavage conditions, the isomerization could not be avoided and resulted in significant loss of material.[10] To identify natural MC-LA, the isomeric mixture was separated by HPLC and the isomers were compared to an authentic sample of the cyanotoxin.[10] The identification of the desired isomers was particularly intricate during the synthesis of unnatural derivatives for which no standard was available.[11]

4

**Scheme 1. Proposed formation of aspartimide II and subsequent isomerization during the saponification of methyl ester protected MC-LA I**



Here, we present an isomerization-free synthetic strategy and its application to the first total synthesis of MC-LF (**1a**) and its deuterated derivative **1b** (Scheme 2) which is of interest as an internal standard during MC quantification by mass spectrometry. Since this approach delivers only one isomer, the synthesis of unnatural MC derivatives becomes feasible which we demonstrate by the preparation of derivative **1c**. The alkyne-labeled **1c** can be employed for toxin derivatization by click chemistry with an azide-containing reporter molecule, e.g. biotin or a fluorescent dye and, furthermore, be used as an activity-based probe to identify interaction partners.[12] According to crystal structures of MCs in complex with protein phosphatases[13] the side chain at position 4 of the MC backbone is not involved in binding and thus represents an optimal position for synthetic modifications.

5

## Results and Discussion

**Scheme 2. Retrosynthetic analysis of MC derivatives 1a-c**



**Retrosynthetic Analysis.** For the synthesis of **1a-c** we followed a fragment-based strategy using *tert*-butyl esters as protecting groups for β-D-MeAsp[3] and γ-D-Glu[6] in order to suppress aspartimide formation.[14] In contrast to the previous approach,[10] in which *N*-methylphosphonylsarcosine was incorporated and subsequently converted into Mdha[7] by a Horner-Wadsworth-Emmons reaction, we incorporated *N*-methylphenylselenocysteine (NMeSecPh) as Mdha precursor that was transformed into Mdha in the final step of the synthesis. For the macrocyclization, we decided to use the peptide bond between residues 4 and 5 which is also the cyclization site during biosynthesis of MCs.[15] In addition, this disconnection has proven reliable in the former synthetic approach.[10]

The linear precursors **2a-c** were synthesized in a convergent manner from fragments **3**, **4** and **5a-c**. Several syntheses of Boc-Adda-OH **3** have been reported.[9a,16] We followed the route developed by Pearson *et al.* that delivers **3** in 13 steps with the best overall yield.[16a] Fmoc groups served as N-terminal protection of fragments **4** and **5a-c**. The presence of Fmoc, *tert*-butyl ester

and the phenylselenocysteine moiety in fragments **4** and **5a-c** required a C-terminal protection which can be cleaved in presence of these three groups and that withstands the conditions of Fmoc deprotection. In our approach we used the phenacyl (Pac) protecting group which is removed under mild reductive conditions.[17] Tetrapeptide **4** and dipeptides **5a-c** were obtained from NMeSecPh derivative **6**,[18] β-D-MeAsp derivative **7** and the building blocks **8a**,[17] **8b**, and **8c**.

**Scheme 3. Synthesis of tetrapeptide fragment 4**[a]



[a]HATU represents 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate.

**Synthesis of Tetrapeptide 4.** We started our synthesis with the preparation of tetrapeptide fragment **4** (Scheme 3). Boc-NMeSecPh-OH **6** was synthesized starting from Boc-*N*-methyl-L-serine **9** using the strategy developed by van der Donk and coworkers for the synthesis of Boc-SecPh-OH[19] and coupled with dipeptide **11** to give **12**.[18] Tripeptide **12** was then deprotected with TFA and coupled with Fmoc-D-Glu-O*t*-Bu to give fragment **4**.

**Scheme 4. Synthesis of Fmoc-D-MeAsp-O*t*-Bu 7**



**Synthesis of Dipeptides 5a-c.** In position 3 of the vast majority of the MCs *erythro*-β-methyl D-aspartic acid (D-MeAsp) is found. Up to date several synthetic routes towards derivatives of this amino acid have been published.[10,16e-g,20] However, all these published approaches feature methyl or ethyl ester protecting groups, which are crucial for the generation of the stereocenter at the β-carbon atom. Since the literature-known building blocks cannot be easily transformed into **7**, we synthesized Fmoc-D-MeAsp-O*t*-Bu **7** starting from D-aspartic acid **13** as shown in Scheme 4. The amino group of **13** was benzylated by reductive amination and the β-carboxy group was regioselectively esterified under acidic conditions to give benzyl ester **14.** The free α-carboxy group of **14** was *tert*-butylated and subsequently the secondary amine was protected with the phenylfluorenyl (PhFl) group to give **15**. This sterically hindered group suppresses deprotonation at the α-carbon and allows enolate formation by selective deprotonation at the β-position of **15** in the subsequent step. Thus, treatment of **15** with lithium bis(trimethylsilyl)amide (LHMDS) followed by addition of methyl iodide led to exclusive methylation of the β-position to give *erythro*-**16** and *threo*-**16** in a ratio of 5:1. The stereoselectivity of this step can be explained by preferred formation of the (*Z*)-lithium enolate which adopts a hydrogen-in-plane conformation that is attacked opposite to the bulky nitrogen protecting groups.[21] The isomers *erythro*-**16** and *threo*-**16** were readily separated by column

chromatography and the configuration of *erythro*-**16** was verified by complete deprotection and subsequent NMR analysis[22] (see Supporting Information)  as well as optical rotation measurement.[20] Hydrogenolysis of *erythro*-**16** followed by Fmoc protection of the free amino group gave building block **7**.

**Scheme 5. A) Synthesis of alkyne labeled building block 8c. B) Synthesis of dipeptide fragments 5a-c**[b]



[b]For definitions of a-c, see Scheme 2

The phenacyl protected propargyl tyrosine building block Boc-Tyr(Prg)-OPac **8c** (Prg = propargyl) was synthesized in three steps starting from Boc-Tyr-OH **17** (Scheme 5A). Double propargylation of **17** followed by saponification of the propargyl ester gave **18** that was alkylated with phenacyl bromide yielding **8c** in a high yield. **8c** as well as literature known **8a**[17] and analogously prepared, isotopically labeled **8b** were N-terminally deprotected and coupled with D-MeAsp derivative **7** to give dipeptides **5a-c** (Scheme 5B)**.**

## Scheme 6. Synthesis of linear heptapeptides 22a-c by fragment couplings[b]



$^{b}$For definitions of a-c, see Scheme 2

**Synthesis of Linear Heptapeptides.** With all fragments in hand, heptapeptides **2a-c** were assembled (Scheme 6). The C-terminal phenacyl ester of tetrapeptide **4** was reductively cleaved to give **19**. Fmoc deprotection of dipeptides **5a-c** was performed with diluted (5%) piperidine in DMF to avoid possible cleavage of the Pac ester giving **20a-c**. The subsequent fragment coupling of **19** and a slight excess of **20a-c** was performed with HATU/collidine leading to **21a-c**. Under these conditions isomerization at the C-terminal Leu residue of fragment **19** is

minimized as it was also reported by others.[10,23] The hexapeptides **21a-c** were N-terminally

deprotected and Boc-Adda-OH **3** was coupled to give heptapeptides **2a-c**. Removal of the Pac

group led to macrocyclization precursors **22a-c**. We found that it was essential to purify

compounds **22a-c** by RP-HPLC to prevent by-product formation during the subsequent

macrocyclization step.

**Scheme 7. Deprotection and macrocyclization**



**Macrocyclization and Final Steps.** The C-termini of **22a-c** were activated as

pentafluorophenyl (Pfp) ester and the *t*-butyl esters along with the Boc group were removed by

TFA treatment (Scheme 7). Macrocyclization was induced under basic conditions applying a

two-phase system of chloroform and phosphate buffer (pH = 9.5) to give cyclopeptides **23a-c**

which were purified by RP-HPLC. According to HPLC approximately 20% (in case of **23a** and

**23b**) and 10% (in case of **23c**), respectively, of an isomeric product, possibly due to

epimerization at C-terminal amino acid during macrocyclization, were observed. Subsequent

selenoxide elimination under mild oxidative conditions gave the desired MC derivatives **1a-c**.

All final products were fully characterized by one- and two-dimensional NMR spectroscopy

and HRMS. The analytical data of synthetic MC-LF (**1a**) were identical to those of a

11

commercial MC-LF sample confirming the structure of the synthetic material. In addition, co-injection of both a mixture of natural and synthetic **1a** as well as a mixture of **1a** and **1b** led to single peaks in the LC-MS chromatograms (Supporting Information).



**Figure 2.** PP1 inhibition assay with natural MC-LF and synthetic compounds **1a**, **1c**, and **23c** (values from three independent experiments). $A_{PP1}$ = activity of PP1

**Inhibition of Protein Phosphatase-1.** In order to confirm that the biological activities of synthetic and natural MC-LF are identical, we determined the potency of both compounds to inhibit the hydrolysis of *p*-nitrophenyl phosphate catalyzed by protein phosphatase-1 (PP1, Figure 2). As expected, the $IC_{50}$ values obtained with this robust assay[24] are very similar within the accuracy of this assay (synthetic **1a**: $IC_{50}$ = 870 pM, natural **1a**: $IC_{50}$ = 1.2 nM) further verifying the authenticity of the synthetic material. We also evaluated the inhibitory potency of the propargylated derivative **1c** and its precursor **23c** lacking the Michael acceptor Mdha. The similar $IC_{50}$ value of **1c** ($IC_{50}$ = 1.7 nM) shows that the modification at position 4 has only a minor influence on phosphatase binding and inhibition as expected from the crystal structure of PP1 in complex with MC-LR.[13b] Phenylselenocystein derivative **23c**, lacking the capability to covalently bind to PP1, has a similar inhibitory potency ($IC_{50}$ = 2.1 nM). Our results show that neither the modification at position 4 nor the one at position 7 of the scaffold disrupt PP1 inhibition. The fact that the absence of the Michael acceptor in compound **23c** does not result in reduced inhibition potency is in line with previous findings that have shown that covalent

12

binding of the toxin to PP1 is a slow process and not required for phosphatase inhibition which is rather achieved by the initial fast non-covalent interaction. However, it is remarkable that the large side chain of NMeSecPh is tolerated during this binding process, thereby dramatically expanding the application domain of derivatized MCs.

## Conclusion

In summary, we developed a novel strategy for the synthesis of MCs. Application of the Fmoc/*t*-Bu protecting group strategy enabled the isomerization-free synthesis of MC-LF as well as a deuterated and an alkyne-labeled derivative thereof. The incorporation of a phenylselenocysteine moiety as precursor for the Mdha residue gave access to a novel potent and reversible phosphatase inhibitor that cannot undergo covalent binding to the protein. The synthesized MC derivatives can be broadly applied for improved MC detection and quantification and pave the way for future approaches to understanding the biological roles of MCs in various organisms.

## Experimental Section

**General Experimental Methods.** Technical solvents (petroleum ether and EtOAc) were distilled prior to use. THF and $CH_2Cl_2$ were distilled from Na/K or $CaH_2$ under inert atmosphere immediately prior to use. Peptide grade DMF was used for peptide couplings. A sample of natural microcystin-LF was obtained from *Enzo Life Sciences* (ALX-350-081-C100, 100 μg) and used as received. The compounds **3**,[16a] **6**,[18] **8a**,[17] and **10**,[18] were synthesized according to the literature. For the reactions performed under inert gas conditions (nitrogen) Schlenk technique and oven dried glassware were used. Analytical thin layer chromatography (TLC)

was performed using TLC silica gel 60 F$_{254}$ coated aluminum sheets (*Merck*). Spots were

visualized either by UV light ($\lambda = 254$ nm) or by dipping and heating using ethanolic ninhydrin

solution (3 % w/v), aqueous potassium permanganate (1 % w/v), anisaldehyde solution (135

mL EtOH, 5 mL conc. H$_2$SO$_4$, 15 mL glacial acetic acid, and 3.7 mL *p*-anisaldehyde), or

Seebach's stain (25 g phosphomolybdic acid, 10 g Ce(SO$_4$)$_2$ · 4H$_2$O, and 60 mL conc. H$_2$SO$_4$

in 1 L H$_2$O). Preparative flash column chromatography (FC) was performed using *Geduran 60*

silica gel (40-60 μm, *Merck*). NMR spectra were recorded on *Bruker Avance III 400* or *Bruker*

*Avance III 600* instruments. Chemical shifts $\delta$ are reported in ppm relative to solvent signals

(CDCl$_3$ $\delta_H = 7.26$ ppm, $\delta_C = 77.2$ ppm; CD$_3$OD $\delta_H = 3.34$ ppm; $\delta_C = 49.0$ ppm; DMSO-*d$_6$* $\delta_H =$

2.50 ppm, $\delta_C = 39.5$ ppm). For all new compounds two-dimensional NMR experiments (COSY,

HSQC, and HMBC) were used for signal assignments. For numbering of carbons see supporting

information.

Semi-preparative and analytical RP-HPLC was performed using a *Shimadzu* LC-20A

prominence system (LC-20AT pumps, SIL-20A auto sampler, CTO-20AC column oven, SPD-

M2OA PDA detector, CBM-20A communication bus module and LC-Solution software). A

Kinetex 5u C18 100A, AXIA (250 x 21.2 mm, *Phenomenex*) column was used as a stationary

phase at a flow rate of 10 mL min$^{-1}$ unless mentioned otherwise. LC-MS measurements were

performed on a *Shimadzu* LCMS-2020 system (LC-20 AD high pressure pumps, SIL-20AT

HAT autosampler, CTO-20AC column oven, SPD-20A UV-Vis detector, CBM-20A

communication bus module, LCMS-2020 ESI-detector and LC-MS-Solution software) using a

Nucleodur 100-3 C18ec (4 x 125 mm, *Macherey-Nagel*) reversed phase column as stationary

phase at a flow rate of 0.4 mL min$^{-1}$. A gradient of water with 0.1 % formic acid (mobile phase

A) and acetonitrile with 0.1 % formic acid (mobile phase B) was used for the HPLC and LC-

MS separations. Elemental analyses were performed by the microanalytical laboratory of the

University of Konstanz using an *Elementar* vario EL instrument. HRMS measurements were

14

performed on a *Bruker* micrOTOF II (ESI-TOF) or a *Thermo* LTQ Orbitrap Discovery (ESI-

Orbitrap) instrument.

**General Procedures**

**GP1: Phenacyl protection**.[17] The amino acid derivative (1.0 equiv) is dissolved in EtOAc.

Then $Et_3N$ (1.1 equiv) and phenacyl bromide (1.1 equiv) are added and the reaction mixture is

stirred at rt for 4h. During the reaction, the formation of a white precipitate can be observed.

After 4h the mixture is diluted with EtOAc and washed with brine (1x), sat. $NaHCO_3$ solution

(1x), and brine (2x). The organic phase is dried over $Na_2SO_4$, filtered, and concentrated under

reduced pressure.

**GP2: Phenacyl deprotection.** The protected peptide is dissolved in MeOH/DMF (8:2, 8 μL

$mg^{-1}$ peptide). Then Mg-turnings (0.16 mg/mg peptide) and acetic acid (0.8 μL $mg^{-1}$ peptide)

are added and the reaction mixture is cooled to 0 °C. After 20 min cooling is removed and the

reaction mixture is stirred at rt for 30 min. The reaction mixture is filtered, the volatiles are

removed under reduced pressure, and the residue is taken up in $CH_2Cl_2$/MeOH (9:1). The

mixture is filtered through 3 $cm^3$ silica column which is extensively washed with

$CH_2Cl_2$/MeOH (9:1). The solvents are removed under reduced pressure and the residue is

lyophilized. The obtained deprotected peptide is used without further purification.

**GP3: Fmoc deprotection**. The peptide is dissolved in 5% piperidine in DMF (v/v). After 3

min, the solution is diluted with DMF and the volatiles are removed under reduced pressure.

The residue is coevaporated with toluene (3x) and used without further purification.

**GP4: Boc/*t*-Bu deprotection**. The starting material is dissolved in neat TFA and stirred at rt

for 30 min. Subsequently the TFA is removed and the residue is coevaporated with toluene,

EtOAc and petroleum ether (each 1x) and used without further purification.

15

**GP5: Fmoc protection.** The amino acid (1.0 equiv) is suspended in $Na_2CO_3$ (10% w/v, 1.25 mL mmol$^{-1}$ amino acid). Then Fmoc-OSu (1.3 equiv) in dioxane (1.875 mL mmol$^{-1}$ amino acid) is added, and the mixture is stirred at rt overnight. The reaction mixture is diluted with $H_2O$ and EtOAc, acidified with aqueous $NaHSO_4$ (1M) to pH < 3, and extracted with EtOAc (3x). The combined organic phases are washed with brine (1x), dried over $Na_2SO_4$, filtered, and the volatiles removed under reduced pressure. The crude product is purified with FC.

**GP6: Peptide coupling.** The amine and carboxylic acid are dissolved in DMF. The resulting solution is cooled to 0 °C. Then base (DIPEA or collidine) and after 5 min the coupling reagent (HATU or HBTU) are added. The resulting yellowish solution is stirred at 0 °C for 45 min and at rt overnight. The reaction mixture is diluted with EtOAc and washed subsequently with $H_2O$, 1:1 diluted saturated citric acid solution, 1:1 diluted saturated $NaHCO_3$ solution, and brine (each 1x). The organic phase is dried over $Na_2SO_4$, filtered, and purified with FC.

**GP7: Macrocylization.** The HPLC-purified C-terminally deprotected heptapeptide (1.0 equiv) is placed in a 4 mL glass vial. Then pentafluorophenol (1.95 equiv), dissolved in freshly distilled EtOAc (24.2 mL mmol$^{-1}$ peptide) and solid DCC are added. The reaction mixture is cooled to 0 °C, stirred for 90 min and then at rt for 8-10h. Afterwards, the solvent is removed and the activated peptide is treated with TFA according to GP4. The resulting C-terminally activated unprotected heptapeptide is dissolved in $CHCl_3$ (515 mL mmol$^{-1}$ peptide). The resulting solution is added dropwise over a period of 10 min to a vigorously mechanically stirred mixture of $CHCl_3$ (875 mL mmol$^{-1}$ peptide) and pH = 9.5 phosphate buffer (1M, 875 mL mmol$^{-1}$ peptide). After 30 min, the reaction mixture is diluted with a small amount of $CHCl_3$ and $H_2O$. The phases are separated, the aqueous phase is acidified with $NaHSO_4$ (1M) to pH < 3 and

16

extracted with EtOAc (3x). The organic phases are combined, washed with brine, and dried

over $Na_2SO_4$. The crude macrocyclic heptapeptide is lyophilized and purified using HPLC.

**GP8: Selenoxide elimination.** The macrocyclic peptide is dissolved in $MeCN/H_2O$ (3:2, 1 mL)

and 30% aqueous $H_2O_2$ (4 μL) is added. After 1h at rt, the reaction mixture is quenched with

$Me_2S$ (50 μL) and purified by HPLC.

**Synthesized Compounds (Sorted According to Compound Number)**

**Microcystin-LF (1a).** The C-terminally unprotected heptapeptide **22a** (15 mg, 10.9 μmol)

was macrocyclized using pentafluorophenol (4.0 mg, 21.3 μmol) and DCC (2.8 mg, 13.3 μmol)

according to GP7. The crude macrocycle **23a** was purified by semi-preparative RP-HPLC

(gradient: 60-90% B in 30 min, $t_R$ = 13.3 min). The cyclic peptide **23a** was transformed to **1a**

according to GP8 and the reaction mixture was separated by semi-preparative RP-HPLC

(gradient: 50-70% B in 20 min, $t_R$ = 13.2 min). MC-LF **1a** was obtained as a white amorphous

solid (2.0 mg, 19%). LC-MS analysis of synthetic **1a** coinjected with natural MC-LF resulted

in a single peak with the expected mass (Figure S3). $^1$H NMR (600 MHz, $CD_3OD$, 300 K)

$\delta$ 8.89 (d, $J$ = 9.6 Hz, 1H, NH MeAsp), 8.17 – 8.08 (m, 2H, NH Leu, NH Phe), 7.46 (d, $J$ = 8.2

Hz, 1H, NH Ala), 7.31 (d, $J$ = 9.2 Hz, 1H, NH Adda), 7.27 – 7.25 (m, 2H, Ar), 7.23 – 7.14 (m,

8H, Ar), 6.35 (d, $J$ = 15.5 Hz, 1H, H-5 Adda), 5.89 (s, 1H, C=CH$_2$), 5.51 (d, $J$ = 9.8 Hz, 1H, H-

7 Adda), 5.45 (s, 1H, C=CH$_2$), 5.43 (dd, $J$ = 15.5, 8.6 Hz  1H, H-4 Adda), 4.74 – 4.69 (m, H-3

Adda), 4.58 – 4.49 (m, 3H, H-$\alpha$ MeAsp, H-$\alpha$ Phe, H-$\alpha$ Ala), 4.45 (t, $J$ = 7.4 Hz, 1H, H-$\alpha$ Glu),

4.22 – 4.18 (m, 1H, H-$\alpha$ Leu), 3.50 (dd, $J$ = 14.1, 3.2 Hz, 1H, H-$\beta$ Phe), 3.38 (s, 3H, -NCH$_3$),

3.30 – 3.27 (m, 1H, H-9 Adda), 3.26 (s, 3H, -OCH$_3$), 2.93 (dq, $J$ = 7.2, 3.3 Hz, 1H, H-$\beta$ MeAsp),

2.84  (dd, $J$ = 14.0, 4.8 Hz, 1H, H-10 Adda), 2.74 – 2.68 (m, 2H, H-10 Adda, H-2 Adda), 2.66

– 2.55 (m, 4H, H-8 Adda, 2x H-$\gamma$ Glu, H-$\beta$ Phe), 2.19 – 2.11 (m, 1H, H-$\beta$ Glu), 1.91 – 1.83 (m,

1H, H-$\beta$ Leu), 1.80 – 1.68 (m, 2H, H-$\beta$ Glu, H-$\gamma$ Leu), 1.65 (s, 3H, 3xH-6' Adda), 1.53 (ddd, $J$

= 13.9, 9.8, 4.2 Hz, 1H, H-β Leu), 1.11 (d, $J$ = 6.9 Hz, 3H, 3xH-2' Adda), 1.04 (d, $J$ = 6.7 Hz,

3H, 3xH-8' Adda), 0.99 (d, $J$ = 7.4 Hz, 3H, CH$_3$ Ala), 0.88 (d, $J$ = 6.6 Hz, 3H, 3xH-δ Leu),

0.86 (d, $J$ = 6.5 Hz, 3H, 3xH-δ Leu), 0.76 (d, $J$ = 7.2 Hz, 3H, CH$_3$ MeAsp); $^{13}$C NMR (151

MHz, CD$_3$OD, 300 K) $\delta$ 178.4 (C=O MeAsp), 176.5 (C=O), 176.4 (C=O), 176.0 (C=O), 175.7

(C=O), 175.2 (C=O), 175.2 (C=O), 171.5 (C=O Phe), 166.0 (C=O Mdha), 146.2 (-$\underline{C}$=CH$_2$),

140.6 (C Ar), 139.4 (C-5 Adda), 139.2 (C Ar), 137.6 (C-7 Adda), 133.7 (C-6 Adda), 130.5 (C

Ar), 130.1 (2xC Ar), 129.5 (2xC Ar), 129.2 (C Ar), 127.9 (C Ar), 127.1 (C Ar), 125.9 (C-4

Adda), 114.4 (-C=$\underline{C}$H$_2$), 88.4 (C-9 Adda), 58.8 (-OCH$_3$), 56.1 (C-7 Adda), 55.3 (C-α MeAsp),

55.3 (C-α Phe), 55.2 (C-α Leu), 53.3 (C-α Glu), 49.6 (C-α Ala), 46.0 (C-2 Adda), 40.8 (C-β

Leu), 40.6 (C-β MeAsp), 39.0 (C-10 Adda), 38.5 (-NCH$_3$), 38.1 (C-β Phe), 37.8 (C-8 Adda),

33.4 (C-γ Glu), 29.5 (C-β Glu), 25.7 (C-γ Leu), 23.5 (C-δ Leu), 21.2 (C-δ Leu), 17.4 (CH$_3$ Ala),

16.5 (C-8' Adda), 16.4 (C-2' Adda), 15.0 (CH$_3$ MeAsp), 12.9 (C-6' Adda). HRMS (ESI-

Orbitrap) m/z: [$M$+H]$^+$ Calcd for C$_{52}$H$_{72}$N$_7$O$_{12}$ 986.52335; Found 986. 52418.

**[Phe-$d_5$$^4$]-Microcystin-LF (1b).** The macrocyclic derivative **23b** (5 mg, 4.35 μmol) was

transformed to **1a** according to GP8, and the reaction mixture was separated by semi-

preparative RP-HPLC (gradient: 50-70% B in 20 min, $t_R$ = 13.6 min). The microcystin **1b** was

obtained as a white amorphous solid (3.3 mg, 76%). LC-MS analysis of synthetic **1b** coinjected

with MC-LF resulted in a single peak with the expected masses of both deuterated **1b** and

undeuterated MC-LF (Figure S4). $^1$H NMR (600 MHz, CD$_3$OD, 284 K) $\delta$ 8.16 (d, $J$ = 6.8 Hz,

1H, NH Leu), 8.07 (d, $J$ = 9.1 Hz, 1H, NH MeAsp), 7.56 (d, $J$ = 8.4 Hz, 1H, NH Ala), 7.27 –

7.25 (m, 2H, Ar), 7.23 – 7.15 (m, 3H, Ar), 6.35 (d, $J$ = 15.5 Hz, 1H, H-5 Adda), 5.89 (s, 1H, -

C=CH$_2$), 5.51 (d, $J$ = 9.9 Hz, 1H, H-7 Adda), 5.46 (s, 1H, -C=CH$_2$), 5.45 (dd, $J$ = 15.6, 8.6 Hz,

1H, H-4 Adda), 4.69 (dd, $J$ = 11.0, 8.7 Hz, 1H, H-3 Adda), 4.58 – 4.49 (m, 3H, H-α MeAsp,

H-α Phe-$d_5$, H-α Ala), 4.40 (t, $J$ = 7.5 Hz, 1H, H-α Glu), 4.23 – 4.13 (m, 1H, H-α Leu), 3.49

18

(dd, $J$ = 14.1, 3.4 Hz, 1H, H-β Phe-$d_5$), 3.37 (s, 3H, -NCH$_3$), 3.30 – 3.28 (m, 1H, H-9 Adda),

3.26  (s, 3H, -OCH$_3$), 2.95 (dq, $J$ = 7.2, 3.5 Hz, 1H, H-β MeAsp), 2.85 (dd, $J$ = 14.0, 4.7 Hz,

1H, H-10 Adda), 2.80 (dd, $J$ = 10.9, 6.9 Hz, 1H, H-2 Adda), 2.69 (dd, $J$ = 13.9, 7.3 Hz, 1H, H-

10 Adda), 2.65 – 2.52 (m, 4H, H-8 Adda, H-β Phe-$d_5$, 2xH-γ Glu), 2.17 – 2.07 (m, 1H, H-β

Glu), 1.90 (ddd, $J$ = 15.5, 12.8, 4.1 Hz, 1H, H-β Leu), 1.80 – 1.69 (m, 2H, H-β Glu, H-γ Leu),

1.65 (s, 3H, 3xH-6' Adda), 1.52 (ddd, $J$ = 13.8, 10.2, 3.9 Hz, 1H, H-β Leu), 1.10 (d, $J$ = 6.9 Hz,

3H, 3xH-2' Adda), 1.04 (d, $J$ = 6.7 Hz, 3H, 3xH-8' Adda), 0.97 (d, $J$ = 7.4 Hz, 3H, -CH$_3$ Ala),

0.88 (d, $J$ = 6.6 Hz, 3H, 3xH-δ Leu), 0.85 (d, $J$ = 6.6 Hz, 3H, 3xH-δ Leu), 0.75 (d, $J$ = 7.2 Hz,

3H, CH$_3$ MeAsp); $^{13}$C NMR (151 MHz, CD$_3$OD, 284 K): $\delta$ = 178.5 (C=O MeAsp), 176.6

(C=O), 176.5 (C=O), 176.2 (C=O), 175.6 (C=O), 175.3 (C=O), 175.2 (C=O), 171.6 (C=O Phe),

166.0 (C=O Mdha), 146.2 (-$\underline{C}$=CH$_2$), 140.5 (C Ar), 139.3 (C-5 Adda), 139.0 (C Ar), 137.5 (C-

7 Adda), 133.7 (C-6 Adda), 130.6 (C Ar), 129.2 (C Ar), 127.1 (C Ar), 126.0 (C-4 Adda), 114.5

(-C=$\underline{C}$H$_2$), 88.3 (C-9 Adda), 58.7 (-OCH$_3$) , 56.2 (C-7 Adda), 55.6 (C-α MeAsp), 55.2 (C-α

Phe-$d_5$),  55.1 (C-α Leu), 53.6 (C-α Glu), 49.6 (C-α Ala), 45.7 (C-2 Adda), 40.8 (C-β Leu),

38.9 (C-10 Adda), 38.5 (-NCH$_3$), 38.0 (C-β Phe-$d_5$), 37.7 (C-8 Adda), 33.4 (C-γ Glu), 29.2 (C-

β Glu), 25.7 (C-γ Leu), 23.6 (C-δ Leu), 21.2 (C-δ Leu), 17.3 (-CH$_3$ Ala), 16.6 (C-8' Adda),

16.3 (C-2' Adda), 15.0 (CH$_3$ MeAsp), 12.9 (C-6' Adda); HRMS (ESI-TOF) m/z: [$M$+H]$^+$ Calcd

for C$_{52}$H$_{67}$D$_5$N$_7$O$_{12}$ 991.5547; Found 991.5553.

**Microcystin-LY(Prg) (1c).** The macrocyclic derivative **23c** (6.2 mg, 5.18 μmol) was

transformed to **1c** according to GP8 and the reaction mixture was separated by semi-preparative

RP-HPLC (gradient: 50-70% B in 20 min, $t_R$ = 14.1 min). The microcystin **1c** was obtained as

a white amorphous solid (2.3 mg, 43 %). $^1$H NMR (600 MHz, CD$_3$OD, 300 K) $\delta$ 8.89 (d, $J$ =

9.6 Hz, 1H, NH Tyr(Prg)), 8.21 (d, $J$ = 8.7 Hz, 1H, NH MeAsp), 8.11 (d, $J$ = 6.7 Hz, 1H, NH

Leu), 7.43 (d, $J$ = 8.0 Hz, 1H, NH Ala), 7.28 – 7.26 (m, 2H, Ar), 7.22 – 7.16 (m, 3H, Ar), 7.09

(d, *J* = 8.6 Hz, 2H, Ar), 6.84 (d, *J* = 8.7 Hz, 2H, Ar), 6.35 (d, *J* = 15.5 Hz, 1H, H-5 Adda), 5.90

(s, 1H, -C=CH$_2$), 5.51 (d, *J* = 9.8 Hz, 1H, H-7 Adda), 5.46 (s, 1H, -C=CH$_2$), 5.42 (dd, *J* = 15.5,

8.7 Hz, 1H, H-4 Adda), 4.71 (dd, *J* = 11.0, 8.6 Hz, 1H, H-3 Adda), 4.65 (d, *J* = 2.3 Hz, 2H, -

OCH$_2$- Tyr(Prg)), 4.57 – 4.50 (m, 3H, H-$\alpha$ MeAsp, H-$\alpha$ Tyr(Prg), H-$\alpha$ Ala), 4.46 (dd, *J* = 8.8,

6.1 Hz, 1H, H-$\alpha$ Glu), 4.22 – 4.15 (m, 1H, H-$\alpha$ Leu), 3.44 (dd, *J* = 14.1, 3.1 Hz, 1H, H-$\beta$

Tyr(Prg)), 3.37 (s, 3H, -NCH$_3$), 3.30 – 3.26 (m, 1H, H-9 Adda), 3.26 (s, 3H, -OCH$_3$), 2.96 –

2.91 (m, 1H, H-$\beta$ MeAsp), 2.91 (t, *J* = 2.4 Hz, 1H, -C≡CH), 2.84 (dd, *J* = 14.0, 4.7 Hz, 1H, H-

10 Adda), 2.73 – 2.66 (m, 2H, H-2 Adda, H-10 Adda), 2.63 (dq, *J* = 9.9, 6.6 Hz, 1H, H-8 Adda),

2.61 – 2.56 (m, 1H, 2xH-$\gamma$ Glu), 2.51 (dd, *J* = 14.1, 11.9 Hz, 1H, H-$\beta$ Tyr(Prg)), 2.19 – 2.11

(m, 1H, H-$\beta$ Glu), 1.89 – 1.83 (m, 1H, H-$\beta$ Leu), 1.79 – 1.73 (m, 1H, H-$\gamma$ Leu), 1.73 – 1.65 (m,

1H, H-$\beta$ Glu), 1.65  (d, *J* = 1 Hz, 3H, 3xH-6' Adda), 1.52 (ddd, *J* = 13.7, 9.8, 4.1 Hz, 1H, H-$\beta$

Leu), 1.11 (d, *J* = 6.9 Hz, 3xH-2' Adda), 1.04 (d, *J* = 6.7 Hz, 3xH-8' Adda), 1.01 (d, *J* = 7.4

Hz, 3H, CH$_3$ Ala), 0.89 (d, *J* = 6.6 Hz, 3H, 3xH-$\delta$ Leu), 0.86 (d, *J* = 6.6 Hz, 3H, 3xH-$\delta$ Leu),

0.81 (d, *J* = 7.2 Hz, 3H, CH$_3$ MeAsp); $^{13}$C NMR (151 MHz, CD$_3$OD, 300 K) $\delta$ 178.4 (C=O

MeAsp), 176.4 (C=O), 175.9 (C=O), 175.8 (C=O), 175.2 (C=O), 175.0 (C=O), 171.5 (C=O),

166.0 (C=O), 165.9 (C=O), 158.0 (-$\underline{C}$-O-CH$_2$-), 146.2 (-$\underline{C}$=CH$_2$), 140.5 (C Ar Adda), 139.4 (C-

5 Adda), 137.7 (C-7 Adda), 133.7 (C-6 Adda), 131.8 (C Ar Tyr(Prg)), 131.1 (2xC Ar Tyr(Prg)),

130.5 (2xC Ar Adda), 129.2 (2xC Ar Adda), 127.1 (CH Ar Adda), 125.8 (C-4 Adda), 116.0

(2xC Ar Tyr(Prg)), 114.4 (-C=$\underline{C}$H$_2$), 88.4 (C-9 Adda), 79.8 (-$\underline{C}$≡CH), 76.8 (-C≡$\underline{C}$H), 58.7 (-

OCH$_3$), 56.5 (-OCH$_2$-), 56.0 (C-3 Adda), 55.4, 55.3, 55.2 (m, 3C, C-$\alpha$ Leu, C-$\alpha$ MeAsp, C-$\alpha$

Tyr(Prg)),  53.2 (C-$\alpha$ Glu), 49.6 (C-$\alpha$ Ala), 46.0 (C-2 Adda), 40.8 (C-$\beta$ Leu), 40.5 (C-$\beta$

MeAsp), 39.0 (C-10 Adda), 38.5 (-NCH$_3$), 37.7 (C-8 Adda), 37.2 (C-$\beta$ Tyr(Prg)), 33.4 (C-$\gamma$

Glu), 29.6 (C-$\beta$ Glu), 25.7 (C-$\gamma$ Leu), 23.5 (CH$_3$ Leu), 21.2 (CH$_3$ Leu), 17.4 (CH$_3$ Ala), 16.5

(C-8' Adda), 16.4 (C-2' Adda), 15.2 (CH$_3$ MeAsp), 12.9 (C-6' Adda); HRMS (ESI-TOF) m/z:

[*M*+H]$^+$ Calcd for C$_{55}$H$_{74}$N$_7$O$_{13}$ 1040.5339; Found 1040.5353.

20

**Fmoc-γ-D-Glu(O*t*-Bu)-N-MeSecPh-D-Ala-Leu-OPac (4).** Tripeptide **12** (297 mg, 449.5 μmol) was deprotected according to GP4. The N-terminally deprotected tripeptide (91 mg, 107.5 μmol) and Fmoc-D-Glu-O*t*-Bu (249 mg, 584.4 μmol) were dissolved in DMF (2 mL). Peptide coupling was performed according to GP6 using HATU (222 mg, 584.4 μmol) and DIPEA (313 μL, 1.8 mmol). The crude product was purified by FC to give tetrapeptide **4** (390 mg, 90%) as a white amorphous solid: $R_f$ = 0.77 (EtOAc); ^{1}H NMR (400 MHz, CDCl$_3$, 300 K) $\delta$ 7.80 – 7.70 (m, 4H, 4x H-Ar), 7.68 – 7.54 (m, 3H, 3x H-Ar), 7.53 – 7.47 (m, 1H, 2x H-Ar), 7.45 – 7.35 (m, 4H, 4x H-Ar), 7.33 – 7.25 (m, 2H, 2x H-Ar), 7.24 – 7.19 (m, 4H, 3x H-Ar, NH Ala), 6.84 (d, *J* = 8.3 Hz, 1H, NH Leu), 5.57 (d, *J* = 8.0 Hz, 1H, NH Glu), 5.35 (dd, *J* = 10.2, 5.3 Hz, 1H, H-α NMeSecPh), 5.19 (d, *J* = 16.5 Hz, 1H, -C(O)CH$_2$-O), 4.94 (d, *J* = 16.5 Hz, 1H, -C(O)CH$_2$-O), 4.65 – 4.53 (m, 2H, H-α Leu, H-α Ala), 4.44 – 4.38 (m, 1H, -OCH$_2$-CH-Fmoc), 4.35 – 4.25 (m, 2H, -OCH$_2$-CH- Fmoc, H-α Glu), 4.17 (t, *J* = 6.9 Hz, 1H, -OCH$_2$-CH-Fmoc), 3.63 (dd, *J* = 13.0, 5.2 Hz, 1H, H-β NMeSecPh), 3.19 (dd, *J* = 12.9, 10.5 Hz, 1H, H-β NMeSecPh), 2.76 (s, 3H, -NCH$_3$), 2.47 – 2.32 (m, 2H, 2x H-γ Glu), 2.18 (dd, *J* = 15.6, 4.4 Hz, 1H, H-β Glu), 1.82 – 1.73 (m, *J* = 3.1 Hz, 2H, H-β Leu, H-γ Leu), 1.70 – 1.60 (m, 2H, H-β Leu, H-β Glu), 1.48 (s, 9H, [t]Bu), 1.36 (d, *J* = 7.1 Hz, 3H, CH$_3$ Ala), 0.97 (d, *J* = 6.3 Hz, 3H, 3xH-δ Leu), 0.95 (d, *J* = 6.3 Hz, 3H, 3xH-δ Leu); ^{13}C NMR (101 MHz, CDCl$_3$, 300 K) $\delta$ 173.4 (C=O), 172.6 (C=O), 172.1 (C=O), 171.7 (C=O), 171.3 (C=O), 170.5 (C=O), 156.5 (C=O), 144.3 (C Ar), 143.8 (C Ar), 141.5 (C Ar), 141.4 (C Ar), 134.1 (C Ar), 134.1 (C Ar), 133.2 (C Ar), 129.8 (C Ar), 129.3 (2C Ar), 129.0 (C Ar), 127.8 (C Ar), 127.8 (C Ar), 127.4 (C Ar), 127.3 (C Ar), 127.3 (C Ar), 125.5 (C Ar) 125.3 (C Ar), 120.0 (2C Ar), 82.7 (-C(CH$_3$)$_3$), 67.0 (-OCH$_2$-CH-Fmoc), 66.3 (CH$_2$ Pac), 58.0 (C-α NMeSecPh), 53.4 (-OCH$_2$-CH- Fmoc), 50.7 (C-α Leu), 48.6 (C-α Ala), 47.2 (C-α Glu), 41.2 (C-β Leu), 32.2 (-NCH$_3$), 28.84 (C-β Glu), 28.75 (C-γ Glu), 28.2 (3C, -C(CH$_3$)$_3$), 26.4 (C-β NMeSecPh), 25.0 (C-γ Leu), 23.1 (C-δ Leu), 21.8 (C-δ Leu)

21

16.1 (CH$_3$ Ala); HRMS (ESI-TOF) m/z: [$M$+H]$^+$ Calcd for C$_{51}$H$_{61}$N$_4$O$_{10}$Se 969.35474; Found 969.35351.

**Fmoc-β-D-MeAsp(O$t$-Bu)-Phe-OH (5a).** Boc-Phe-OPac[17] **8a** (120 mg, 313 μmol) was deprotected according to GP4. The obtained H-Phe-OPac and Fmoc-D-MeAsp-O$t$-Bu **7** (140 mg, 329 μmol) were dissolved in DMF (3 mL). Peptide coupling was performed according to GP6 using HATU (125 mg, 329 μmol) and DIPEA (165 μL, 329 μmol). The crude product was purified by FC (petroleum ether/EtOAc 2:1) to give dipeptide **5a** (153 mg, 71%) as a white amorphous solid: $R_f$ = 0.77 (petroleum ether/EtOAc 1:1); $^1$H NMR (400 MHz, CDCl$_3$, 300 K) $\delta$ 7.95 – 7.87 (m, 2H, Ar), 7.76 (d, $J$ = 7.6 Hz, 2H, Ar), 7.65 – 7.60 (m, 2H, Ar), 7.52 – 7.48 (m, 2H, Ar), 7.40 – 7.37 (m, 2H, Ar), 7.34 – 7.20 (m, 8H, Ar), 6.13 – 6.05 (m, 1H, NH MeAsp, NH Phe), 5.50 (d, $J$ = 16.3 Hz, 1H, CH$_2$ Pac), 5.34 (d, $J$ = 16.3 Hz, 1H, CH$_2$ Pac), 5.01 (ddd, $J$ = 13.0, 7.4, 5.5 Hz, 1H, H-α Phe), 4.41 (dd, $J$ = 10.2, 7.2 Hz, 1H, -OCH$_2$-CH- Fmoc), 4.36 – 4.28 (m, 2H, -OCH$_2$-CH- Fmoc, H-α MeAsp), 4.24 (t, $J$ = 7.2 Hz, 1H, -OCH$_2$-CH- Fmoc), 3.42 (dd, $J$ = 14.2, 5.6 Hz, 1H, H-β Phe), 3.19 (dd, $J$ = 14.2, 7.1 Hz, 1H, H-β Phe), 3.04 (qd, $J$ = 7.3, 3.8 Hz, 1H, H-β MeAsp), 1.41 (s, 9H, $t$-Bu), 1.15 (d, $J$ = 7.3 Hz, 3H, CH$_3$ MeAsp); $^{13}$C NMR (101 MHz, CDCl$_3$, 300 K) $\delta$ 191.4 (C=O), 173.6 (C=O), 171.2 (C=O), 170.1 (C=O), 157.1 (C=O), 144.2 (C Ar), 144.0 (C Ar), 141.4 (C Ar), 135.9 (C Ar), 134.3 (C Ar), 134.1 (C Ar), 129.6 (2C Ar), 129.1 (2C, Ar), 128.8 (2C Ar), 127.9 (2C Ar), 127.8 (2C Ar), 127.4 (C Ar), 127.2 (2C Ar), 127.2 (C Ar), 125.5 (C Ar), 125.4 (C Ar), 120.1 (C Ar) 120.0 (C Ar), 82.5 (-C(CH$_3$)$_3$), 67.3 (-OCH$_2$-CH- Fmoc), 66.7 (CH$_2$ Pac), 57.1 (-OCH$_2$-CH- Fmoc), 53.0 (C-α Phe), 47.3 (C-α MeAsp), 41.6 (C-β MeAsp), 37.8 (C-β Phe), 28.0 (3C, -C(CH$_3$)$_3$), 15.2 (CH$_3$ MeAsp); HRMS (ESI-TOF) m/z: [$M$+H]$^+$ Calcd for C$_{41}$H$_{43}$N$_2$O$_8$ 691.30139; Found 691.30123.

**Fmoc-β-D-MeAsp(O$t$-Bu)-Phe-$d_5$-OH (5b).** Boc-Phe-$d_5$-OPac **8b** (43 mg, 109.7 μmol) was deprotected according to GP4. The obtained H-Phe-$d_5$-OPac and Fmoc-D-MeAsp-O$t$-Bu **7** (49

22

mg, 115.0 μmol) were dissolved in DMF (1 mL). Peptide coupling was performed according to GP6 using HATU (44 mg, 115.0 μmol) and DIPEA (57.2 μL, 329.0 μmol). The crude product was purified by FC (petroleum ether/EtOAc 2:1) to give dipeptide **5b** (66 mg, 86%) as a white amorphous solid: $R_f$ = 0.77 (petroleum ether/EtOAc 1:1); $^1$H NMR (400 MHz, CDCl$_3$, 300 K) $\delta$ 7.93 – 7.87 (m, 2H, Ar), 7.76 (d, $J$ = 7.6 Hz, 2H, Ar), 7.66 – 7.59 (m, 3H, Ar), 7.52 – 7.48 (m, 2H, Ar), 7.40 – 7.48 (m, 2H, Ar), 7.32 – 7.27 (m, 2H, Ar), 6.12 – 6.03 (m, 2H, NH MeAsp, NH Phe-$d_5$), 5.50 (d, $J$ = 16.3 Hz, 1H, CH$_2$ Pac), 5.34 (d, $J$ = 16.3 Hz, 1H, CH$_2$ Pac), 5.01 (ddd, $J$ = 13.0, 7.2, 5.5 Hz, 1H, H-$\alpha$ Phe), 4.41 (dd, $J$ = 10.2, 7.2 Hz, 1H, -OC<u>H</u>$_2$-CH- Fmoc), 4.36 – 4.28 (m, 2H, -OC<u>H</u>$_2$-CH- Fmoc, H-$\alpha$ MeAsp), 4.24 (t, $J$ = 7.3 Hz, 1H, -OCH$_2$-C<u>H</u>- Fmoc), 3.42 (dd, $J$ = 14.2, 5.6 Hz, 1H, H-$\beta$ Phe), 3.19 (dd, $J$ = 14.2, 7.1 Hz, 1H, H-$\beta$ Phe), 3.04 (qd, $J$ = 7.1, 3.9 Hz, 1H, H-$\beta$ MeAsp), 1.41 (s, 9H, $t$-Bu), 1.15 (d, $J$ = 7.2 Hz, 3H, CH$_3$ MeAsp); $^{13}$C NMR (101 MHz, CDCl$_3$, 300 K) $\delta$ 191.4 (C=O), 173.6 (C=O), 171.2 (C=O), 170.1 (C=O), 157.1 (C=O), 141.4 (C Ar), 134.3 (C Ar), 134.1 (C Ar), 129.1 (2C Ar), 127.9 (2C Ar), 127.8 (2C Ar), 127.2 (2C Ar), 125.5 (C Ar), 125.4 (C Ar), 120.1 (2C Ar), 82.5 (-<u>C</u>(CH$_3$)$_3$), 67.4 (-O<u>C</u>H$_2$-CH-Fmoc), 66.7 (CH$_2$ Pac), 56.1 (-OCH$_2$-<u>C</u>H- Fmoc), 53.0 (C-$\alpha$ Phe-$d_5$), 47.4 (C-$\alpha$ MeAsp), 41.6 (C-$\beta$ MeAsp), 37.7 (C-$\beta$ Phe-$d_5$), 28.0 (3C, -C(<u>C</u>H$_3$)$_3$), 15.2 (CH$_3$ MeAsp); HRMS (ESI-TOF) m/z: [$M$+H]$^+$ Calcd for C$_{41}$H$_{38}$D$_5$N$_2$O$_8$ 696.3328; Found 696.3313.

**Fmoc-β-D-MeAsp(O*t*-Bu)-Tyr(Prg)-OH (5c).** Boc-Tyr(Prg)-OPac **8c** (137 mg, 313 μmol) was deprotected according to GP4. The obtained H-Tyr(Prg)-OPac and Fmoc-D-MeAsp-O*t*-Bu **7** (140 mg, 329 μmol) were dissolved in DMF (3 mL). Peptide coupling was performed according to GP6 using HATU (125 mg, 329 μmol) and DIPEA (165 μL, 329 μmol). The crude product was purified by FC to give dipeptide **5c** (181 mg, 84%) as a white amorphous solid: $R_f$ = 0.3 (petroleum ether/EtOAc 2:1); $^1$H NMR (400 MHz, CDCl$_3$, 300 K) $\delta$ 7.94 – 7.86 (m, 2H, Ar), 7.75 (d, $J$ = 7.5 Hz, 2H, Ar), 7.67 – 7.58 (m, 3H, Ar), 7.52 – 7.48 (m, 2H, Ar), 7.40 – 7.36

(m, 2H, Ar), 7.31 – 7.27 (m, 2H, Ar), 7.17 (d, $J$ = 8.6 Hz, 2H, Ar), 6.94 – 6.90 (m, 2H, Ar), 6.11 – 6.03 (m, 2H, NH MeAsp, NH Phe), 5.50 (d, $J$ = 16.3 Hz, 1H, $CH_2$ Pac), 5.33 (d, $J$ = 16.3 Hz, 1H, $CH_2$ Pac), 4.97 (ddd, $J$ = 13.3, 6.8, 6.0 Hz, 1H, H-$\alpha$ Tyr(Prg)), 4.65 (d, $J$ = 2.3 Hz, 2H, -$OCH_2$- Tyr(Prg)), 4.42 (dd, $J$ = 10.1, 7.2 Hz, 1H, -O$\underline{C}H_2$-CH- Fmoc), 4.37 – 4.30 (m, 2H, H-$\alpha$ MeAsp, -O$\underline{C}H_2$-CH- Fmoc), 4.29 – 4.21 (m, 1H, -$OCH_2$-C$\underline{H}$- Fmoc), 3.36 (dd, $J$ = 14.3, 5.8 Hz, 1H, H-$\beta$ Tyr(Prg)), 3.16 (dd, $J$ = 14.3, 6.8 Hz, 1H, H-$\beta$ Tyr(Prg)), 3.05 (qd, $J$ = 7.3, 3.5 Hz, 1H, H-$\beta$ MeAsp), 2.49 (t, $J$ = 2.2 Hz, 1H, -C≡CH), 1.41 (s, 9H, $t$-Bu), 1.17 (d, $J$ = 7.2 Hz, 3H, $CH_3$ MeAsp); $^{13}C$ NMR (101 MHz, CDCl$_3$, 300 K) $\delta$ 191.4 (C=O), 173.6 (C=O), 171.2 (C=O), 170.1 (C=O), 157.1 (C=O) 156.9 (C Ar), 141.4 (C Ar) , 134.3 (C Ar), 134.1 (C Ar), 130.7 (2C, Ar), 129.1 (2C, Ar), 128.8 (C Ar), 127.9 (2C, Ar), 127.8 (2C, Ar), 127.2 (C Ar), 127.2 (C Ar), 125.5 (C Ar), 125.4 (C Ar), 120.1 (C Ar), 115.2 (2C, Ar), 82.5 (-$\underline{C}$(CH$_3$)$_3$), 78.7 (-$\underline{C}$≡CH), 75.7 (-C≡$\underline{C}$H), 67.4 (-O$\underline{C}H_2$-CH- Fmoc), 66.7 ($CH_2$ Pac), 57.1 (C-$\alpha$ MeAsp), 56.0 (-O$CH_2$- Tyr(Prg)), 53.1 (C-$\alpha$ Tyr(Prg)), 47.3 (m, 1H, -O$CH_2$-$\underline{C}H$- Fmoc), 41.6 (C-$\beta$ MeAsp), 36.9 (C-$\beta$ Tyr(Prg)), 28.0 (3C, -C($\underline{C}H_3$)$_3$), 15.3 (CH$_3$ MeAsp); HRMS (ESI-TOF) m/z: [$M$+H]$^+$ Calcd for C$_{44}$H$_{45}$N$_2$O$_9$ 745.31196; Found 745.31092.

**Fmoc-D-MeAsp-O$t$-Bu (7).** The amino acid *erythro*-**16** (1.00 g, 1.6 mmol) was suspended in methanol (13 mL) and 10% Pd/C catalyst (410 mg, wet, 53.7% water) was added. The reaction mixture was hydrogenated overnight at slightly positive hydrogen pressure and filtered through a Celite pad. The residue was further treated according to GP5 using Fmoc-OSu (703 mg, 2.084 mmol), dioxane (3 mL) and 10% w/v aqueous Na$_2$CO$_3$ (2 mL). The crude product was purified with FC (petroleum ether/EtOAc/AcOH 74:25:1) to give **7** (572 mg, 84%) as a white amorphous solid: $R_f$ = 0.5 (petroleum ether/EtOAc/AcOH 49:50:1); mp 55-57 °C; [$\alpha$]$_D^{27}$ +11.8 (*c* 1.0, MeCN); $^1H$ NMR (400 MHz, CDCl$_3$, 300 K) $\delta$ 7.76 (d, $J$ = 7.5 Hz, 2H, Ar), 7.62 (d, $J$ = 7.4 Hz, 2H, Ar), 7.42 – 7.38 (m, 2H, Ar), 7.34 – 7.29 (m, 2H, Ar), 5.75 (d, $J$ = 8.9 Hz, 1H, NH), 4.59 (dd, $J$ = 8.9, 3.6 Hz, 1H, H-$\alpha$), 4.49 – 4.34 (m, 2H, $CH_2$ Fmoc), 4.25 (t, $J$ = 7.1 Hz, 1H,

24

CH Fmoc), 3.30 (qd, J = 7.3, 3.6 Hz, 1H, H-β) 1.46 (s, 9H, $^t$Bu), 1.27 (d, $J$ = 7.3 Hz, 3H, CH$_3$);

$^{13}$C NMR (101 MHz, CDCl$_3$, 300 K) $\delta$ 178.7 (C=O), 169.7 (C=O), 156.7 (C=O Fmoc), 144.1

(C Ar), 143.9 (C Ar), 141.5 (2C Ar), 127.9 (2C Ar), 127.2 (2C Ar), 125.3 (2C Ar), 120.1 (C

Ar), 120.1 (C Ar), 83.2 (-$\underline{C}$(CH$_3$)$_3$), 67.4 (CH$_2$ Fmoc), 56.2 (C-α), 47.3 (CH Fmoc), 41.5 (C-β),

28.0 (3C, -C($\underline{C}$H$_3$)$_3$), 13.0 (CH$_3$); HRMS (ESI-TOF) m/z: [2$M$+H]$^+$ Calcd for C$_{48}$H$_{55}$N$_2$O$_{12}$

851.3750; Found 851.3708; Anal. Calcd for C$_{24}$H$_{27}$NO$_6$: C, 67.75; H, 6.40; N, 3.29. Found: C

67.64; H, 6.50; N, 3.38.

**Boc-Phe-$d_5$-OPac (8b)** Boc-Phe-$d_5$-OH (390 mg, 1.44 mmol) was dissolved in EtOAc (6 mL)

and reacted according to GP1. The product **8b** was obtained as a white amorphous solid (260

mg, 46%): $R_f$ = 0.55 (petroleum ether/EtOAc 7:3); $^1$H NMR (400 MHz, CDCl$_3$, 300 K) $\delta$ 7.91

(d, $J$ = 7.7 Hz, 2H, Ar), 7.62 (t, $J$ = 7.4 Hz, 1H, Ar), 7.50 (t, $J$ = 7.7 Hz, 2H, Ar), 5.49 (d, $J$ =

16.3 Hz, 1H, CH$_2$ Pac), 5.31 (d, $J$ = 16.4 Hz, 1H, CH$_2$ Pac), 4.97 (d, $J$ = 7.7 Hz, 1H, NH), 4.77

– 4.72 (m, 1H, H-α), 3.35 (dd, $J$ = 14.1, 5.3 Hz, 1H, H-β), 3.15 (dd, $J$ = 14.0, 7.0 Hz, 1H, H-

β), 1.40 (s, 9H, $^t$Bu); $^{13}$C NMR (101 MHz, CDCl$_3$, 300 K): $\delta$ = 191.7 (C=O), 171.8 (C=O),

155.3 (C Ar), 134.2 (C Ar), 129.1 (2C, Ar), 127.9 (2C, Ar), 80.1 (-$\underline{C}$(CH$_3$)$_3$), 66.6 (CH$_2$ Pac),

54.5 (C-α), 38.2 (C-β), 28.4 (3C, -C($\underline{C}$H$_3$)$_3$); HRMS (ESI-TOF) m/z: [2$M$+H]$^+$ Calcd for

C$_{44}$H$_{41}$D$_{10}$N$_2$O$_{10}$ 777.4166; Found 777.4151.

**Boc-Tyr(Prg)-OPac (8c).** The carboxylic acid **18** (350 mg, 1.10 mmol) was dissolved in

EtOAc (5.5 mL) and reacted according to GP1. The product **8c** was obtained as a white

amorphous solid (421 mg, 90%): $R_f$ = 0.55 (petroleum ether/EtOAc 7:3); mp 94-95 °C; [α]$_D^{25}$

-21.2 (c 0.5, MeCN); $^1$H NMR (400 MHz, CDCl$_3$, 300 K) $\delta$ 7.95 – 7.88 (m, 2H, Ar), 7.65 –

7.60 (m, 1H, Ar), 7.50 (t, $J$ = 7.7 Hz, 2H, Ar), 7.19 (d, $J$ = 8.5 Hz, 2H, Ar), 6.94 – 6.90 (m, 2H

Ar), 5.50 (d, $J$ = 16.4 Hz, 1H, CH$_2$ Pac), 5.30 (d, $J$ = 16.3 Hz, 1H, CH$_2$ Pac), 4.95 (d, $J$ = 7.9

Hz, 1H, NH), 4.74 – 4.69 (m, 1H, H-α), 4.67 (d, $J$ = 2.4 Hz, 2H, -OCH$_2$- Tyr(Prg)), 3.29 (dd, $J$

25

= 14.2, 5.4 Hz, 1H, H-β), 3.11 (dd, $J$ = 14.0, 6.7 Hz, 1H, H-β), 2.51 (t, $J$ = 2.4 Hz, 1H, -C≡CH), 1.41 (s, 9H, tBu); $^{13}$C NMR (101 MHz, CDCl$_3$, 300 K) $\delta$ 191.7 (C=O), 171.8 (C=O), 156.8 (-C-O-CH$_2$-), 155.3 (C=O), 134.2 (C Ar), 130.7 (2C, Ar), 129.2 (C Ar), 129.1 (2C, Ar), 127.9 (2C, Ar), 115.1 (C Ar), 80.1 (-$\underline{C}$(CH$_3$)$_3$), 78.8 (-$\underline{C}$≡CH), 75.6 (-C≡$\underline{C}$H), 66.5 (CH$_2$ Pac), 56.0 (-OCH$_2$- Tyr(Prg)), 54.5 (C-α), 37.5 (C-β), 28.4 (3C, -C($\underline{C}$H$_3$)$_3$); HRMS (ESI-TOF) m/z: [$M$+H]$^+$ Calcd for C$_{25}$H$_{28}$NO$_6$: 438.19111; Found 438.19216; Anal. Calcd for C$_{25}$H$_{27}$NO$_6$: C, 68.64; H, 6.22; N, 3.20. Found: C, 68.56; H, 6.11; N, 3.32.

**Boc-N-MeSecPh-D-Ala-Leu-OPac (12).**[18] Boc-Leu-OPac[17] (500 mg, 1.43 mmol) was deprotected according to GP4. Then H-Leu-OPac, Boc-D-Ala-OH (325 mg, 1.72 mmol) and HOBt (232 mg, 1.72 mmol) were dissolved in CH$_2$Cl$_2$ (5 mL) and coupled according to GP6 using HBTU (651 mg, 1.72 mmol) and DIPEA (980 μL, 5.72 mmol). The crude product was purified by FC to give Boc-D-Ala-Leu-OPac[18] (500 mg, 83%) as a white solid: $R_f$ = 0.66 (PE/EtOAc 1:1); The analytical data for Boc-D-Ala-Leu-OPac were in agreement with the published ones.[18] The dipeptide Boc-D-Ala-Leu-OPac (502 mg, 1.195 mmol) was deprotected according to GP4 to give H-D-Ala-Leu-OPac **11** that was immediately used in the next step. Crude deprotected dipeptide **11** (1.195 mmol) and Boc-NMeSecPh-OH **6** (471 mg, 1.314 mmol) were dissolved in DMF (5 mL) and coupled according to GP6 using HATU (500 mg, 1.314 mmol) and DIPEA (832 μL, 4.778 mmol). The crude product was purified by FC (petroleum ether/EtOAc 1:1) to give title compound **12** (683 mg, 90%) as a white amorphous solid. The analytical data for **12** were in agreement with the published ones.[18] $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 7.92 – 7.81 (dd, $J$ = 8.5, 1.3 Hz, 2H, Ar), 7.62 (dt, $J$ = 7.5, 1.3 Hz, 1H, Ar), 7.54 – 7.45 (m, 4H, Ar), 7.27 – 7.23 (m, 3H, Ar), 6.79 (b, 1H, NH Leu), 6.53 (b, 1H, NH Ala), 5.47 (d, $J$ = 16.3 Hz, 1H, CH$_2$ Pac), 5.22 (d, $J$ = 16.3 Hz, 1H, CH$_2$ Pac), 4.69 (b, 1H, H-α Leu), 4.50 (b, 2H, H-α Ala, H-α NMeSecPh), 3.60 (dd, $J$ = 13.0, 5.9 Hz, 1H, H-β NMeSecPh), 3.16 (b, 1H, H-β NMeSecPh), 2.80 (s, 3H, -NMe), 1.90 – 1.66 (m, 3H, 2xH-β Leu, H-γ Leu), 1.45

26

(s, 9H, $^t$Bu), 1.38 (d, $J$ = 6.9 Hz, 1H, Ala), 0.99 (d, $J$ = 6.3, Hz, 3H, CH$_3$ Leu), 0.97 (d, $J$ = 6.3 Hz, 3H, CH$_3$ Leu).

**Bn-D-Asp(OBn)-OH (14).** Starting from Bn-D-Asp-OH (8.61 g, 38.6 mmol), compound **14** (10.16 g, 84%) was prepared according to a procedure published for the synthesis of Bn-L-Asp(OBn)-OH.[25] The analytical data of **14** were in agreement with the data published for its enantiomer.[25] $^1$H NMR (400 MHz, DMSO-$d_6$, 300 K) $\delta$ 7.43 – 7.18 (m, 10H, Ar), 5.10 (s, 2H, 1H, -COOCH$_2$-), 3.92 (d, $J$ = 13.4 Hz, 1H, N-CH$_2$-), 3.80 (d, $J$ = 13.4 Hz, 1H, N-CH$_2$-), 3.55 (t, $J$ = 6.6 Hz, 1H, H-$\alpha$), 2.80 (dd, $J$ = 16.0, 6.2 Hz, 1H, H-$\beta$), 2.70 (dd, $J$ = 16.0, 7.1 Hz, 1H, H-$\beta$); $^{13}$C NMR (101 MHz, DMSO-$d_6$, 300 K) $\delta$ 170.9 (C=O), 170.1 (C=O), 150.0 (C Ar), 136.8 (C Ar), 136.2 (C Ar), 129.9 (C Ar), 129.0 (C Ar), 128.9 (2C, Ar), 128.6 (C Ar), 128.4 (2C, Ar), 128.0 (C Ar), 124.4 (C Ar), 66.5 (-COO$\underline{C}$H$_2$-), 56.1 (C-$\alpha$), 50.4 (N-CH$_2$-), 35.4 (C-$\beta$).

**Bn-D-Asp(OBn)-O$t$-Bu.** Bn-D-Asp(OBn)-OH **14** (4.0 g, 12.8 mmol) was suspended in $t$-BuOAc (72 mL) and 70% aqueous perchloric acid (1.840 mL, 15.2 mmol) was added dropwise. After stirring for 18h at rt, water (40 mL) was added and the phases were separated. The aqueous phase was extracted with EtOAc (1x 30 mL). The organic phases were combined and washed with saturated NaHCO$_3$ solution (3x). During the workup, formation of a white precipitate could be observed. The organic phase was filtered, washed with brine and dried with Na$_2$SO$_4$. The volatiles were removed and Bn-D-Asp(OBn)-O$t$-Bu was obtained as a pale yellow oil (3.168 g, 67%). The analytical data for Bn-D-Asp(OBn)-O$t$-Bu were in agreement with the data published for its enantiomer.[25] [$\alpha$]$_D^{26}$ +17.5 ($c$ 1.0, MeCN); $^1$H NMR (400 MHz, CDCl$_3$, 300 K) $\delta$ 7.38 – 7.21 (m, 10H, Ar), 5.15 (d, $J$ = 12.3 Hz, 1H, -COOCH$_2$-) 5.11 (d, $J$ = 12.3 Hz, 1H, -COOCH$_2$-), 3.87 (d, $J$ = 12.9 Hz, 1H, N-CH$_2$-), 3.71 (d, $J$ = 12.9 Hz, 1H, N-CH$_2$-), 3.59 (dd, $J$ = 7.1, 5.9 Hz, 1H, H-$\alpha$), 2.75 (dd, $J$ = 15.6, 5.9 Hz, 1H, H-$\beta$), 2.67 (dd, $J$ = 15.6, 7.2 Hz,

1H, H-β), 1.45 (s, 9H, *t*-Bu); ^{13}C NMR (101 MHz, CDCl₃, 300 K) $\delta$ 172.8 (C=O), 171.0 (C=O), 139.9 (C Ar), 135.9 (C Ar), 128.7 (C Ar), 128.5 (2C Ar), 128.4 (2C Ar), 128.4 (C Ar), 128.4 (C Ar), 127.2 (C Ar), 81.8 (-$\underline{C}$(CH₃)₃), 66.6 (-COO$\underline{C}$H₂-), 58.0 (C-α), 52.2 (N-CH₂-), 38.6 (C-β), 28.2 (3C, -C($\underline{C}$H₃)₃).

**(2*R*)-4-Benzyl-1-tert-butyl-*N*-benzyl-*N*-(9-phenylfluoren-9-yl)-aspartate (15).** To the solution of Bn-D-Asp(OBn)-O*t*-Bu (1.587 g, 4.274 mmol) in dry acetonitrile (47 mL) anhydrous K₃PO₄ (1.088 g, 5.192 mmol) and phenylfluorenyl bromide (1.324 g, 4.122 equiv) were added. The resulting heterogenic mixture was mechanically stirred for 24h at rt, filtered, and the solvent was removed. The crude product was purified by FC to give 15 (1.870 g, 72%) as a white solid. The analytical data for **15** were in agreement with the data published for its enantiomer.[25] $R_f$ = 0.25 (petroleum ether/EtOAc 15:1); [α]$_D^{29}$ -25.0 (*c* 1.0, MeCN); ^{1}H NMR (400 MHz, CDCl₃, 300 K) $\delta$ 7.82 (d, *J* = 7.1 Hz, 2H, Ar), 7.74 (d, *J* = 7.5 Hz, 1H, Ar), 7.66 (d, *J* = 7.4 Hz, 1H, Ar), 7.60 (d, *J* = 7.5 Hz, 1H, Ar), 7.56 (d, *J* = 7.5 Hz, 1H, Ar), 7.47 (d, *J* = 7.0 Hz, 2H, Ar), 7.37 (td, *J* = 7.5, 1.0 Hz, 1H, Ar), 7.34 – 7.16 (m, 11H, Ar), 7.11 – 7.05 (m, 2H, Ar), 4.87 (d, *J* = 12.5 Hz, 1H, -COOCH₂-), 4.80 (d, *J* = 12.5 Hz, 1H, -COOCH₂-), 4.22 (d, *J* = 13.8 Hz, 1H, N-CH₂-), 3.93 (dd, *J* = 10.9, 2.6 Hz, 1H, H-α), 3.85 (d, *J* = 13.9 Hz, 1H, N-CH₂-), 2.61 (dd, *J* = 15.8, 10.9 Hz, 1H, H-β), 1.98 (dd, *J* = 15.9, 2.7 Hz, 1H, H-β), 1.08 (s, 9H, *t*-Bu); ^{13}C NMR (101 MHz, CDCl₃, 300 K) $\delta$ 171.3 (C=O), 171.2 (C=O), 147.7 (C Ar), 146.4 (C Ar), 143.8 (C Ar), 141.0 (C Ar), 140.3 (C Ar), 139.0 (C Ar), 136.0 (C Ar), 129.7 (2C Ar), 128.7 (2C Ar), 128.5 (2C Ar), 128.5 (2C Ar), 128.2 (2C Ar), 128.1 (C Ar), 128.0 (2C Ar), 127.7 (C Ar), 127.7 (C Ar), 127.4 (2C Ar), 127.3 (C Ar), 127.1 (C Ar), 126.7 (C Ar), 120.6 (C Ar), 120.0 (2C Ar), 80.8 (-$\underline{C}$(CH₃)₃), 79.7 ($\underline{C}$-Ph), 66.0 (-COO$\underline{C}$H₂-), 57.6 (C-α), 51.8 (N-CH₂-), 34.4 (C-β), 27.8 (3C, -C($\underline{C}$H₃)₃); Anal. Calcd for C₄₁H₃₉NO₄: C, 80.76; H, 6.45; N, 2.30. Found: C, 80.58; H, 6.53; N, 2.46.

28

**(2*R*,3*S*)-4-Benzyl-1-tert-butyl-*N*-benzyl-*N*-(9-phenylfluoren-9-y1)-3-methylaspartate (*eryhtro*-16).** A solution of LHMDS in THF (1.0 M, 8.25 mL, 8.25 mmol) was placed in a Schlenk flask under nitrogen atmosphere and cooled to < -20 °C. First a solution of aspartic acid derivative **15** (2.0 g, 3.28 mmol in dry THF (15 mL) and then a solution of methyl iodide (707 μL, 11.35 mmol) in dry THF (11 mL) were added slowly. The mixture was stirred for 3h at < -20 °C and 30 min at room temperature and quenched with sat. aqueous $NH_4Cl$ (10 mL) and water (10 mL). The phases were separated and the aqueous phase was extracted with EtOAc (100 mL). The combined organic phases were washed with brine (1x), dried over $Na_2SO_4$, filtered and the solvents were removed. The crude product was purified by FC to give *eryhtro*-**16** (1.17 g, 57%) as a white solid: $R_f$ = 0.4 (petroleum ether/EtOAc 15:1) mp 115.5 °C; $[\alpha]_D^{26}$ +250.0 (*c* 1.0, MeCN); ^{1}H NMR (400 MHz, $CDCl_3$, 300 K) $\delta$ 7.83 (d, *J* = 7.4 Hz, 1H, Ar), 7.73 (d, *J* = 7.4 Hz, 1H, Ar), 7.62 (d, *J* = 6.9 Hz, 3H, Ar), 7.56 (d, *J* = 7.7 Hz, 1H, Ar), 7.47 (d, *J* = 7.0 Hz, 2H, Ar), 7.44 – 7.08 (m, 15H, Ar), 5.14 (d, *J* = 12.4 Hz, 1H, -COOCH$_2$-), 5.02 (d, *J* = 12.4 Hz, 1H, -COOCH$_2$-), 4.67 (d, *J* = 14.3 Hz, 1H, CH$_2$ N-Bn), 4.26 (d, *J* = 14.3 Hz, 1H, CH$_2$ N-Bn), 3.97 (d, *J* = 9.9 Hz, 1H, H-$\alpha$), 2.75 (dq, *J* = 9.9, 7.0 Hz, 1H, H-$\beta$), 1.06 (s, 9H, *t*-Bu), 0.79 (d, *J* = 7.1 Hz, 3H, CH$_3$); ^{13}C NMR (101 MHz, $CDCl_3$, 300 K) $\delta$ 174.2 (-COOBn), 170.3 (-COO*t*-Bu), 147.1 (C Ar), 146.0 (C Ar), 145.3 (C Ar), 142.2 (C Ar), 142.0 (2C, Ar), 139.6 (C Ar), 136.2 (C Ar), 129.2 (2C, Ar), 128.7 (C Ar), 128.6 (2C, Ar), 128.4 (2C, Ar), 128.3 (C Ar), 128.3 (C Ar), 128.2 (2C, Ar), 128.2 (2C, Ar), 128.0 (2C, Ar), 127.7 (C Ar), 127.6 (C Ar), 127.5 (2C, Ar), 127.4 (C Ar), 127.0 (C Ar), 126.7 (C Ar), 80.9 (-C(CH$_3$)$_3$), 80.5 (C-Ph), 66.1 (CH$_2$ Bn), 64.0 (C-$\alpha$), 51.7 (CH$_2$ Bn), 42.5 (C-$\beta$), 27.8 (3C, -C(CH$_3$)$_3$), 15.4 (CH$_3$); Anal. Calcd for $C_{42}H_{41}NO_4$: C, 80.87; H, 6.63; N, 2.25. Found: C, 80.84; H, 6.67; N, 2.42.

**H-β-D-MeAsp-OH, ((3*S*)-β-D-methylaspartic acid).** The amino acid *erythro*-**16** (200 mg, 1.6 mmol) was suspended in methanol (2.84 mL) and 10% Pd/C catalyst (82 mg, wet, 53.7% water) was added. The reaction mixture was hydrogenated overnight at a slightly positive

29

hydrogen pressure and filtered through a syringe filter. The filtrate was diluted 1:1 with aqueous

HCl (0.1 M) and filtered twice through a syringe filter. The volatiles were removed and the

residue was coevapotated with EtOAc (1x) and toluene (2x). The resulting solid was treated

with TFA (0.7 mL) according to GP4. The crude product was purified by HPLC (1% B isocratic

over 10 min, $t_R$ = 4.0 min) to give the formic acid salt of H-β-D-MeAsp-OH[20] as a white

amorphous solid (40 mg, 85%). The optical rotation ($[\alpha]^D_{23.5}$ -35.91 (*c* 1.07, 5M HCl)) was in

agreement with published values for H-β-D-MeAsp-OH ($[\alpha]^D_{22}$ -31.0 (*c* 2.00, 5M HCl))[20] and

enantiomeric (3*R*)-β-l-methylaspartic acid ($[\alpha]^D_{21}$ +34.3 (*c* 2.05, 5M HCl)).[26] A coupling

constant $^3J_{C\alpha H-C\beta H}$ of 9.0 Hz determined by $^1$H NMR (400 MHz, D2O, 300 K, pD > 14)

additionally verifies the *erythro* configuration of H-β-D-MeAsp-OH.[22] $^1$H NMR (400 MHz,

D2O, 300 K, pD > 14) $\delta$ 2.58 (d, *J* = 9.0 Hz, 1H, H-α), 1.75 (dq, *J* = 8.9, 7.2 Hz, 1H, H-β),

0.44 (d, *J* = 7.1 Hz, 3H, -CH3).

**N-(*tert*-Butoxycarbonyl)-*O*-prop-2-yn-1-yl-L-tyrosine    (Boc-Tyr(Prg)-OH)    (18).**[27]

2-tert-Butoxycarbonylamino-3-[4-(prop-2-ynyloxy)phenyl]-propionic acid propargyl ester[28]

(3.633 g, 10.17 mmol) was dissolved in 1M KOH solution in methanol (20.34 mL, 20.34 mmol)

and sonicated for 2h at 35 °C. The methanol was removed under reduced pressure. The residue

was dissolved in H2O (30 mL) and the aqueous phase was washed with Et2O (2x30 mL). The

aqueous phase was acidified with KHSO4 (1 M) to pH = 2 and extracted with EtOAc (2x30

mL). The EtOAc extracts were combined, washed with brine, dried over MgSO4, and the

volatiles were removed under reduced pressure. Product 18 was obtained as a white amorphous

solid (3.1 g, 95%) and used without further purification. The analytical data for 18 were in

agreement with the published ones.[27] $^1$H NMR (400 MHz, CDCl3) $\delta$ 7.12 (d, *J* = 8.5 Hz, 2H,

Ar), 6.92 (d, *J* = 8.6 Hz, 2H, Ar), 4.92 (d, *J* = 7.0 Hz, 1H, NH), 4.92 (d, *J* = 2.4 Hz, 2H, -OCH2),

4.56 (b, 1H, H-α), 3.14 (dd, *J* = 13.9, 5.2 Hz, 1H, H-β), 3.04 (dd, *J* = 13.8, 5.5 Hz, 1H, H-β),

2.51 (t, *J* = 2.3 Hz, 1H, -C≡CH), 1.42 (s, 9H, *t*-Bu).

**Fmoc-γ-D-Glu(O*t*-Bu)-N-MeSecPh-D-Ala-Leu-β-D-MeAsp(O*t*-Bu)-Phe-OH**                    **(21a).**

Tetrapeptide **4** (61 mg, 63 μmol) and dipeptide **5a** (50 mg, 72 μmol) were deprotected according

to GP2 and GP3, respectively. The products **19** and **20a** were dissolved in DMF (1 mL) and

coupled according to GP6 using HATU (28 mg, 74 μmol) and collidine (25 μL, 188 μmol). The

crude product was purified by FC (CH$_2$Cl$_2$/*i*-PrOH 99:1 to 95:5) to give **21a** (49 mg, 60%) as a

white amorphous solid: $R_f$ = 0.65 (CH$_2$Cl$_2$/*i*-PrOH 95:5); ^{1}H NMR (600 MHz, DMSO-$d_6$, 360

K) $\delta$ 8.22 (d, $J$ = 8.0 Hz, 1H, NH), 7.94 (d, $J$ = 7.3 Hz, 2H, Ar), 7.86 (d, $J$ = 7.5 Hz, 2H, Ar),

7.69 – 7.66 (m, 4H, 3x H-Ar, NH), 7.61 (s, 1H, NH), 7.60 – 7.52 (m, 3H, 2x H-Ar, NH), 7.49

(d, $J$ = 6.9 Hz, 2H, Ar), 7.40 (t, $J$ = 7.4 Hz, 2H, Ar), 7.31 (t, $J$ = 7.4 Hz, 2H, Ar), 7.29 – 7.22

(m, 7H, Ar), 7.21 – 7.17 (m, 1H, Ar), 5.45 (d, $J$ = 16.4 Hz, 1H, CH$_2$ Pac), 5.42 (d, $J$ = 16.4 Hz,

1H, CH$_2$ Pac), 5.08 – 5.00 (b, 1H, H-α NMeSecPh), 4.72 (td, $J$ = 8.8, 5.0 Hz, 1H, H-α Phe),

4.36 – 4.26 (m, 4H, H-α MeAsp, H-α Ala, -OCH$_2$-CH- Fmoc), 4.25 – 4.19 (m, 2H, H-α Leu, -

OCH$_2$-CH- Fmoc), 4.03 – 3.98 (m, 1H, H-α Glu), 3.52 – 3.45 (m, 1H, H-β Phe), 3.25 (dd, $J$ =

14.1, 5.0 Hz, 1H, H-β Phe), 3.17 – 3.11 (m, 1H, H-β NMeSecPh), 2.99 (dd, $J$ = 14.2, 9.4 Hz,

1H, H-β Phe), 2.96 – 2.93 (m, 1H, H-β MeAsp), 2.87 (bs, 3H, -NCH$_3$), 2.42 – 2.34 (m, 2H, 2x

H-γ Glu), 2.06 – 1.99 (m, 1H, H-β Glu), 1.93 – 1.83 (m, 1H, H-β Glu), 1.63 – 1.55 (m, H-γ

Leu), 1.53 – 1.48 (m, 2H, 2x H-β Leu), 1.41 (s, 9H, *t*-Bu), 1.34 (s, 9H, *t*-Bu), 1.22 (d, $J$ = 6.8

Hz, 3H, CH$_3$ Ala), 0.88 (d, $J$ = 7.1 Hz, 3H, CH$_3$ MeAsp), 0.85 (d, $J$ = 6.6 Hz, 3H, 3xH-δ Leu),

0.80 (d, $J$ = 6.5 Hz, 3H, 3xH-δ Leu); HRMS (ESI-TOF) m/z: [$M$+H]$^+$ Calcd for C$_{69}$H$_{85}$N$_6$O$_{14}$Se

1301.52835; Found 1301.52994.

**Fmoc-γ-D-Glu(O*t*-Bu)-N-MeSecPh-D-Ala-Leu-β-D-MeAsp(O*t*-Bu)-Phe-*d₅*-OH**                    **(21b).**

Tetrapeptide **4** (150 mg, 164.5 μmol) and dipeptide **5b** (110 mg, 158.1 μmol) were deprotected

according to GP2 and GP3, respectively. The crude peptides **19** and **20b** were dissolved in DMF

(1 mL) and coupled according to GP6 using HATU (90 mg, 237.2 μmol) and collidine (160

µL, 1207 µmol). The crude product was purified by FC (CH$_2$Cl$_2$/*i*-PrOH 99:1 to 95:5) to give

**21b** (180 mg, 87%) as a white amorphous solid: $R_f$ = 0.65 (CH$_2$Cl$_2$/*i*-PrOH 95:5); The ^{1}H NMR

spectrum (400 MHz) recorded at 300 K showed two sets of signals (ratio approx. 5:1) and peak

broadening due to the occurrence of two rotamers of the N-methylated amide bond; due to

incomplete H/D-exchange some remaining NH-protons are visible. ^{1}H NMR (400 MHz,

CD$_3$OD, 300 K) $\delta$ 8.68 (d, $J$ = 8.8 Hz, 1H, NH), 7.97 – 7.87 (m, 4H, 2x H-Ar, 2x NH), 7.78 (d,

$J$ = 7.6 Hz, 2H, Ar), 7.71 (d, $J$ = 7.7 Hz, 1H, NH), 7.62 (t, $J$ = 6.9 Hz, 3H, Ar), 7.51 – 7.42 (m,

4H, Ar), 7.37 (t, $J$ = 7.4 Hz, 1H, Ar), 7.31 – 7.19 (m, 5H, Ar), 7.04 (d, $J$ = 8.6 Hz, 1H, NH) 5.49

– 5.46 (m, 2H, CH$_2$ Pac), 4.88 (dd, $J$ = 9.7, 4.1 Hz, 1H, H-α Phe-*d$_5$*), 4.44 – 4.38 (m, 1H, H-α

Ala), 4.37 – 4.21 (m, 5H, H-α Leu, -OCH$_2$-C<u>H</u>- Fmoc, H-α Ala, -OC<u>H</u>$_2$-CH- Fmoc), 4.20 –

4.08 (m, 2H, H-α NMeSecPh, H-α Glu), 3.66 (dd, $J$ = 13.3, 5.0 Hz, 1H, H-β NMeSecPh), 3.47

(dd, $J$ = 13.3, 9.7 Hz, 1H, H-β NMeSecPh), 3.40 (dd, $J$ = 14.1, 4.3 Hz, 1H, H-β Phe-*d$_5$*), 3.20

(s, 3H, -NCH$_3$, minor rotamer), 3.11 (s, 3H, -NCH$_3$, major rotamer), 3.05 – 2.94 (m, 2H, H-β

Phe-*d$_5$*, H-β MeAsp), 2.54 – 2.44 (m, 1H, H-γ Glu), 2.25 – 2.11 (m, 2H, H-β Glu, H-γ Glu),

2.00 – 1.89 (m, 1H, H-β Leu), 1.87 – 1.71 (m, 2H, H-γ Leu, H-β Glu), 1.61 – 1.48 (m, 1H, H-

β Leu), 1.45 (s, 9H, *t*-Bu), 1.38 (s, 9H, *t*-Bu), 1.19 (d, $J$ = 7.3 Hz, 3H, CH$_3$ Ala), 0.97 (d, $J$ =

6.6 Hz, 3H, 3xH-δ Leu), 0.86 (m, 6H, 3xH-δ Leu, CH$_3$ MeAsp); HRMS (ESI-Orbitrap) m/z:

[$M$+H]$^+$ Calcd for C$_{69}$H$_{80}$D$_5$N$_6$O$_{14}$Se 1306.55973; Found 1306. 56074.

**Fmoc-γ-D-Glu(O*t*-Bu)-N-MeSecPh-D-Ala-Leu-β-D-MeAsp(O*t*-Bu)-Tyr(Prg)-OH (21c).**
Tetrapeptide **4** (130 mg, 134 µmol) and dipeptide **5c** (109 mg, 146 µmol) were deprotected

according to GP2 and GP3, respectively. The products **19** and **20c** were dissolved in DMF (1

mL) and coupled according to GP6 using HATU (56 mg, 146 µmol) and collidine (53 µL, 403

µmol). The crude product was purified by FC (CH$_2$Cl$_2$/*i*-PrOH 99:1 to 95:5) to give **21c** (116

mg, 76%) as a white amorphous solid: $R_f$ = 0.63 (CH$_2$Cl$_2$/*i*-PrOH 95:5); ^{1}H NMR (600 MHz,

DMSO-$d_6$, 360 K) $\delta$ 8.19 (d, $J$ = 7.3 Hz, 1H, NH), 7.94 (d, $J$ = 7.2 Hz, 2H, Ar), 7.86 (d, $J$ = 7.5 Hz, 2H, Ar), 7.71 – 7.65 (m, 3H, 3x H-Ar, NH), 7.60 (d, $J$ = 8.6 Hz, 2H, 2x NH), 7.55 (t, $J$ = 7.7 Hz, 2H, Ar), 7.49 (d, $J$ = 8.1 Hz, 2H, Ar), 7.40 (t, $J$ = 7.4 Hz, 2H, Ar), 7.31 (t, $J$ = 7.4 Hz, 2H, Ar), 7.29 – 7.22 (m, 4H, 3x H-Ar, NH), 7.18 (d, $J$ = 8.6 Hz, 2H, Ar), 6.89 (d, $J$ = 8.6 Hz, 2H, Ar), 5.46 – 5.41 (m, 2H, CH$_2$ Pac), 5.08 – 5.00 (m, 1H, H-$\alpha$ NMeSecPh), 4.72 (d, $J$ = 2.3 Hz, 2H, -OCH$_2$- Tyr(Prg)), 4.66 (td, $J$ = 8.6, 5.3 Hz, 1H, H-$\alpha$ Tyr(Prg)), 4.36 – 4.26 (m, 4H, H-$\alpha$ MeAsp, H-$\alpha$ Ala, -OC$\underline{H}_2$-CH- Fmoc), 4.25 – 4.19 (m, 2H, H-$\alpha$ Leu, -OCH$_2$-C$\underline{H}$- Fmoc), 4.01 (dd, $J$ = 13.4, 8.4 Hz, 1H, H-$\alpha$ Glu), 3.52 – 3.46 (m, 1H, H-$\beta$ NMeSecPh), 3.32 (t, $J$ = 2.3 Hz, 1H, -C≡CH), 3.18 (dd, $J$ = 14.3, 5.1 Hz, 1H, H-$\beta$ Tyr(Prg)), 3.16 – 3.12 (m, 1H, H-$\beta$ NMeSecPh), 2.99 – 2.91 (m, 2H, H-$\beta$ Tyr(Prg), H-$\beta$ MeAsp), 2.87 (bs, 3H, -NCH$_3$), 2.44 – 2.35 (m, 2H, 2x H-$\gamma$ Glu), 2.06 – 1.99 (m, 1H, H-$\beta$ Glu), 1.93 – 1.85 (m, 1H, H-$\beta$ Glu), 1.63 – 1.56 (m, 1H, H-$\gamma$ Leu), 1.53 – 1.48 (m, 2H, 2x H-$\beta$ Leu), 1.41 (s, 9H, $t$-Bu), 1.34 (s, 9H, $t$-Bu), 1.23 (d, $J$ = 6.9 Hz, 3H, CH$_3$ Ala), 0.91 (d, $J$ = 7.2 Hz, 3H, CH$_3$ MeAsp), 0.85 (d, $J$ = 6.6 Hz, 3H, 3xH-$\delta$ Leu), 0.81 (d, $J$ = 6.5 Hz, 3H, 3xH-$\delta$ Leu); HRMS (ESI-TOF) m/z: [$M$+H]$^+$ Calcd for C$_{72}$H$_{87}$N$_6$O$_{15}$Se 1355.53891; Found 1355.54122.

**Boc-Adda-$\gamma$-D-Glu(O$t$-Bu)-N-MeSecPh-D-Ala-Leu-$\beta$-D-MeAsp(O$t$-Bu)-Phe-OH (22a).**
The hexapeptide **21a** (100 mg, 77.0 µmol) was N-terminally deprotected according to GP3. The deprotected peptide was coupled with Boc-Adda-OH **3**[16a] (31 mg, 70.0 µmol) according to GP6 using HATU (29 mg, 70.0 µmol) and collidine (28 µL, 210 µmol) in DMF (1 mL). The crude product was purified by FC (95:5 CH$_2$Cl$_2$/$i$-PrOH, $R_f$ = 0.55) to give phenacyl protected heptapeptide **2a** as a white amorphous solid. The phenacyl group of **2a** (50 mg, 33.5 µmol) was removed according to GP2 and the crude product was purified by semi-preparative RP-HPLC (gradient: 75-100% B in 20 min, $t_R$ = 19.9 min) to give **22a** as a white solid (30 mg, 31% from **21a**). $^1$H NMR (600 MHz, DMSO-$d_6$, 360 K) $\delta$ 7.91 (d, $J$ = 4.7 Hz, 1H, NH), 7.82 (d, $J$ = 7.0

Hz, 1H, NH), 7.77 (d, $J$ = 6.9 Hz, 1H, NH), 7.68 (b, 1H, NH), 7.50 – 7.49 (m, 2H, Ar), 7.30 –

7.21 (m, 7H, Ar), 7.21 – 7.14 (m, 6H, Ar), 6.27 (s, 1H, NH), 6.09 (d, $J$ = 15.7 Hz, 1H, H-5

Adda), 5.48 (dd, $J$ = 15.7, 6.6 Hz, 1H, H-4 Adda), 5.38 (d, $J$ = 9.6 Hz, 1H, H-7 Adda), 5.12 –

5.05 (m, 1H, H-α NMeSecPh), 4.50 – 4.44 (m, 1H, H-α Phe), 4.32 – 4.28 (m, 1H, H-α Ala),

4.26 – 4.20 (m, H-α Leu, H-α MeAsp), 4.15 – 4.12 (b, 1H, H-α Glu), 4.09 (dd, $J$ = 15.1, 6.9

Hz, 1H, H-3 Adda), 3.51 (d, $J$ = 12.1 Hz, 1H, H-β NMeSecPh), 3.27 – 3.23 (m, 1H, H-9 Adda),

3.18 (s, 3H, -OCH$_3$), 3.10 (b, 2H, H-β Phe, H-β NMeSecPh), 2.94 – 2.91 (m, 1H, H-β MeAsp),

2.88 (dd, $J$ = 13.9, 8.8 Hz, 1H, H-β Phe), 2.83 (s, 3H, -NCH$_3$), 2.74 (dd, $J$ = 14.0, 4.8 Hz, 1H,

H-10 Adda), 2.66 (dd, $J$ = 14.0, 7.3 Hz, 1H, H-10 Adda), 2.61 – 2.54 (m, 2H, H-2 Adda, H-8

Adda), 2.38 – 2.29 (m, 2H, 2xH-γ Glu), 2.03 – 1.97 (m, 1H, H-β Glu), 1.87 -1.80 (m, 1H, H-β

Glu), 1.62 – 1.58 (m, 1H, H-γ Leu), 1.56 (s, 3H, 3xH-6' Adda), 1.52 – 1.48 (m, 2H, H-β Leu),

1.40 (s, 9H, *t*-Bu), 1.38 (s, 9H, *t*-Bu), 1.36 (s, 9H, *t*-Bu), 1.23 (d, $J$ = 7.1 Hz, 3H, CH$_3$ Ala), 1.05

(d, $J$ = 7.0 Hz, 3H, 3xH-2' Adda), 0.97 (d, $J$ = 6.8 Hz, 3H, 3xH-8' Adda), 0.90 (d, $J$ = 7.1 Hz,

3H, CH$_3$ MeAsp), 0.86 (d, $J$ = 6.6 Hz, 3H, 3xH-δ Leu), 0.82 (d, $J$ = 6.5 Hz, 3H, 3xH-δ Leu);

HRMS (ESI-TOF) m/z: [$M$+H]$^+$ Calcd for C$_{71}$H$_{104}$N$_7$O$_{15}$Se 1374.67624; Found 1374.67841.

**Boc-Adda-γ-D-Glu(O*t*-Bu)-N-MeSecPh-D-Ala-Leu-β-D-MeAsp(O*t*-Bu)-Phe-*d$_5$*-OH**

**(22b).** The hexapeptide **21b** (90 mg, 69.0 μmol) was N-terminally deprotected according to

GP3. The deprotected peptide was coupled with Boc-Adda-OH **3**[16a] (25 mg, 58.0 μmol)

according to GP6 using HATU (33 mg, 87.0 μmol) and collidine (20 μL, 145 μmol) in DMF

(2 mL). The crude product and purified by FC (95:5 CH$_2$Cl$_2$/*i*-PrOH, $R_f$ = 0.55) to give phenacyl

protected heptapeptide **2b** as a white solid. The phenacyl group of **2b** (63 mg, 42.1 μmol) was

removed according to GP2 and the crude product was purified by semi-preparative RP-HPLC

(gradient: 75-100% B in 20 min, $t_R$ = 18.5 min) to give **22b** as a white amorphous solid (23 mg,

25% from **21b**). The $^1$H NMR spectrum (600 MHz) recorded at 300 K showed two sets of

signals (ratio approx. 2:1) and peak broadening due to the occurrence of two rotamers of the N-methylated amide bond. $^1$H NMR (600 MHz, CD$_3$OD, 300 K) $\delta$ 7.56 – 7.52 (m, 2H, Ar), 7.33 – 7.27 (m, 3H, Ar), 7.26 – 7.23 (m, 2H, Ar), 7.20 – 7.14 (m, 3H, Ar), 6.22 (d, $J$ = 15.5 Hz, 1H, H-5 Adda), 5.59 – 5.51 (m, 1H, H-4 Adda), 5.39 (d, $J$ = 9.7 Hz, 1H, H-7 Adda), 4.62 – 4.55 (m, 1H, H-$\alpha$ Phe-$d_5$), 4.36 – 4.29 (m, 5H, H-$\alpha$ Glu, H-$\alpha$ Leu, H-$\alpha$ Ala, H-$\alpha$ Mdha), 4.25 – 4.19 (m, 1H, H-3 Adda major rotamer), 4.06 – 4.03 (m, 1H, H-3 Adda major rotamer), 3.67 (d, $J$ = 12.7 Hz, 1H, 1H, H-$\beta$ NMeSecPh), 3.41 – 3.35 (m, 1H, H-$\beta$ NMeSecPh), 3.22 (s, 1H, 3H, -OCH$_3$), 3.27 – 3.17 (m, 2H, H-$\beta$ Phe-$d_5$, H-9 Adda), 3.11 – 2.99 (m, 1H, H-$\beta$ MeAsp), 3.05 (s, 3H, -NCH$_3$), 2.93 (dd, $J$ = 13.8, 9.2 Hz, 1H, H-$\beta$ Phe-$d_5$), 2.80 (dd, $J$ = 13.9, 3.7 Hz, 1H, H-10 Adda), 2.66 (dd, $J$ = 13.9, 7.4 Hz, 2H, H-10 Adda, H-2 Adda), 2.59 (dq, $J$ = 16.7, 6.7 Hz, 1H, H-8 Adda), 2.45 – 2.39 (m, 1H, H-$\gamma$ Glu), 2.36 – 2.25 (m, 2H, H-$\gamma$ Glu, H-$\beta$ Glu major rotamer), 2.06 – 1.98 (m, 1H, H-$\beta$ Glu minor rotamer) 1.95 – 1.87 (m, 1H, H-$\beta$ Leu), 1.78 – 1.68 (m, 2H, H-$\gamma$ Leu, H-$\beta$ Glu), 1.62 (s, 3H, 3xH-6' Adda), 1.58 – 1.51 (m, 1H, H-$\beta$ Leu), 1.46 (s, 9H, *t*-Bu), 1.42 (s, 9H, *t*-Bu), 1.41 (s, 9H, *t*-Bu), 1.25 (d, $J$ = 7.4 Hz, 3H, CH$_3$ Ala), 1.16 (s, 3H, 3xH-2' Adda), 1.02 (d, $J$ = 6.7 Hz, 3H, 3xH-8' Adda), 0.96 (d, $J$ = 6.6 Hz, 3H, CH$_3$ MeAsp), 0.91 (d, $J$ = 7.1 Hz, 3H, 3xH-$\delta$ Leu), 0.88 (d, $J$ = 6.5 Hz, 3H, 3xH-$\delta$ Leu); HRMS (ESI-Orbitrap) m/z: [$M$+H]$^+$ Calcd for C$_{71}$H$_{99}$D$_5$N$_7$O$_{15}$Se 1379.70640; Found 1379. 70814.

**Boc-Adda-$\gamma$-D-Glu(O*t*-Bu)-N-MeSecPh-D-Ala-Leu-$\beta$-D-MeAsp(O*t*-Bu)-Tyr(Prg)-OH**

**(22c).** The hexapeptide **21c** (110 mg, 81.2 μmol) was N-terminally deprotected according to GP3. The deprotected peptide was coupled with Boc-Adda-OH **3**[16a] (33 mg, 73.8 μmol) according to GP6 using HATU (31 mg, 81.2 μmol) and collidine (30 μL, 226 μmol) in DMF (1 mL). The crude product was purified by FC (95:5 CH$_2$Cl$_2$/*i*-PrOH) to give phenacyl protected heptapeptide **2c** as a white solid (85 mg). The phenacyl group of **2c** (50 mg, 33.5 μmol) was removed according to GP2 and the crude product was purified by semi-preparative RP-HPLC

(gradient: 75-100% B in 20 min, $t_R$ = 18.4 min) to give **22c** as a white amorphous solid (34 mg, 54% from **21c**). The ^{1}H NMR spectrum (600 MHz) recorded at 300 K showed two sets of signals (ratio approx. 2:1) and peak broadening due to the occurrence of two rotamers of the N-methylated amide bond. ^{1}H NMR (600 MHz, CD₃OD, 300 K) $\delta$ 7.55 (d, $J$ = 6.2 Hz, 2H, Ar), 7.32 – 7.27 (m, 3H, Ar), 7.25 (t, $J$ = 7.5 Hz, 2H, Ar), 7.20 – 7.16 (m, 3H, Ar), 7.12 (d, $J$ = 7.7 Hz, 2H, Ar), 6.88 (d, $J$ = 8.5 Hz, 2H, Ar), 6.22 (d, $J$ = 15.8 Hz, 1H, H-5 Adda), 5.59 – 5.51 (m, 1H, H-4 Adda), 5.39 (d, $J$ = 9.8 Hz, 1H, H-7 Adda), 4.67 (d, $J$ = 2.2 Hz, 2H, -OCH₂-), 4.59 – 4.53 (m, 1H, H-α Tyr(Prg)), 4.40 – 4.28 (m, 5H, H-α Leu, H-α Glu, H-α Ala, H-α MeAsp, H-α NMeSecPh), 4.23 (b, 1H, H-3 Adda), 3.69 – 3.63 (m, 1H, H-β NMeSecPh major rotamer), 3.57 – 3.51 (m, 1H, H-β NMeSecPh minor rotamer), 3.40 – 3.35 (m, 1H, H-β NMeSecPh major rotamer) 3.22 (s, 3H, -OCH₃), 3.23 – 3.18 (m, 1H, H-9 Adda), 3.16 – 3.11 (m, 1H, H-β Tyr(Prg)), 3.04 (b, 3H, -NCH₃, H-β MeAsp), 2.91 (s, 1H, -C≡CH), 2.87 (dd, $J$ = 13.9, 9.4 Hz, 1H, H-β Tyr(Prg)), 2.80 (dd, $J$ = 13.8, 3.7 Hz, 1H, H-10 Adda), 2.68 – 2.63 (m, 2H, H-2 Adda, H-10 Adda), 2.63 – 2.56 (m, 1H, H-8 Adda), 2.44 – 2.37 (m, 1H, H-γ Glu), 2.34 – 2.25 (m, 2H, H-γ Glu, H-β Glu major rotamer), 2.04 – 1.98 (m, 1H, H-β Glu minor rotamer) 1.95 – 1.88 (m, 1H, H-β Leu), 1.78 – 1.68 (m, 2H, H-γ Leu H-β Glu), 1.62 (s, 3H, 3xH-6' Adda), 1.61 – 1.51 (m, 1H, H-β Leu), 1.46 (s, 9H, *t*-Bu), 1.42 (s, 18H, 2x*t*-Bu), 1.25 (d, $J$ = 7.4 Hz, 3H, CH₃ Ala), 1.19 – 1.12 (b, 3H, 3xH-2' Adda), 1.02 (d, $J$ = 6.7 Hz, 3H, 3xH-8' Adda), 0.96 (d, $J$ = 6.6 Hz, 3H, 3xH-δ Leu), 0.93 (d, $J$ = 7.2 Hz, 3H, CH₃ MeAsp), 0.88 (d, $J$ = 6.5 Hz, 3H, 3xH-δ Leu); ^{13}C NMR (151 MHz, CD₃OD, 300 K): $\delta$ = 177.1 (C=O), 176.3 (C=O), 175.8 (C=O), 172.4 (C=O), 175.2 (C=O), 172.6 (C=O), 171.8 (C=O), 170.4 (C=O), 158.1 (-C-O-CH₂-), 140.6 (C, Ar), 137.2 (C-7 Adda), 137.0 (C-5 Adda), 134.0 (C-6 Adda), 133.9 (2C, Ar), 131.3 (2C, Ar), 131.1 (C, Ar), 130.5 (2C, Ar), 130.4 (2C, Ar), 129.2 (2C, Ar), 128.3 (C, Ar), 127.1 (C-4 Adda), 127.1 (2C, Ar), 116.0 (2C, Ar), 88.4 (C-9 Adda), 83.2 (-C(CH₃)₃), 82.9 (-C(CH₃)₃), 80.5 (-C(CH₃)₃), 79.9 (-C≡CH), 76.8 (-C≡CH), 64.0 (C-α), 58.8 (-OCH₃), 56.7 (C-α), 56.6 (-OCH₂-),

36

55.9 (C-α), 54.9 (C-α), 53.8 (C-α), 53.5 (C-α), 50.7 (C-α Ala), 45.3 (C-2 Adda), 41.9 (-NCH$_3$),

41.2 (C-β Leu), 39.1 (C-10 Adda), 37.9 (C-β Tyr(Prg)), 37.8 (C-8 Adda), 37.7 (C-β MeAsp),

30.8 (C-γ Glu), 28.8 (3C, -C(CH$_3$)$_3$), 28.4 (3C, -C(CH$_3$)$_3$), 28.4 (C-β Glu), 28.2 (3C, -C(CH$_3$)$_3$),

27.0 (C-β NMeSecPh), 25.8 (C-γ Leu), 23.9 (C-δ Leu), 21.3 (C-δ Leu), 17.5 (CH$_3$ Ala), 16.6

(C-8' Adda), 16.3 (CH$_3$ MeAsp), 15.7 (C-2' Adda), 13.2 (C-6' Adda); HRMS (ESI-Orbitrap)

m/z: $[M+H]^+$ Calcd for C$_{74}$H$_{106}$N$_7$O$_{16}$Se 1428.68558; Found 1428. 68698.

**[Phe-$d_5$$^4$, NMeSecPh$^7$]-Microcystin-LF (23b).** The heptapeptide **22b** (21.7 mg, 15.7 μmol)

was macrocyclized using pentafluorophenol (5.7 mg, 30.7 μmol) and DCC (4 mg, 19.2 μmol)

according to GP7. The crude product was purified by semi-preparative RP-HPLC (gradient: 50-

75% B in 25 min, $t_R$ = 20.5 min) and macrocyclic peptide **23b** was obtained as a white

amorphous solid (5 mg, 28%). $^1$H NMR (600 MHz, CD$_3$OD, 300 K) δ 8.04 – 8.02 (m, 1H, NH

MeAsp), 8.00 (d, $J$ = 6.4 Hz, 1H, NH Leu), 7.51 (d, $J$ = 7.7 Hz, 2H, Ar), 7.35 – 7.29 (m, 3H,

Ar), 7.27 – 7.24 (m, 2H, Ar), 7.22 – 7.14 (m, 4H, 3xH-Ar, NH Ala), 6.32 (d, $J$ = 15.5 Hz, 1H,

H-5 Adda), 5.49 (d, $J$ = 9.7 Hz, 1H, H-7 Adda), 5.43 (dd, $J$ = 15.4, 9.0 Hz, H-4 Adda), 4.65 –

4.59 (m, 1H, H-3 Adda), 4.48 (dd, $J$ = 12.0, 3.6 Hz, 1H, H-α Phe-$d_5$), 4.46 – 4.39 (m, 2H, H-α

MeAsp, H-α Ala), 4.19 – 4.12 (m, 2H, H-α Glu, H-α Leu), 4.04 (dd, $J$ = 9.7, 4.9 Hz, 1H, H-α

NMeSecPh), 3.73 – 3.66 (m, 2H, 2xH-β NMeSecPh), 3.47 – 3.41 (m, 1H, H-β Phe-$d_5$), 3.31 –

3.27 (m, 1H, H-9 Adda) 3.26 (s, 3H,-OCH$_3$), 3.19 (s, -NCH$_3$), 2.93 (dd, $J$ = 7.0, 3.0 Hz, 1H, H-

β MeAsp), 2.84 (dd, $J$ = 14.0, 4.6 Hz, 1H, 1H, H-10 Adda), 2.81 – 2.76 (m, 1H, H-2 Adda),

2.70 (dd, $J$ = 13.9, 7.2 Hz, 1H, H-10 Adda), 2.66 – 2.59 (m, 1H, H-8 Adda), 2.55 (dd, $J$ = 14.2,

11.9 Hz, 1H, H-β Phe-$d_5$), 2.20 – 2.13 (m, 1H, H-γ Glu), 1.96 – 1.89 (m, 1H, H-β Leu), 1.84 –

1.75 (m, 2H, H-β Glu, H-γ Leu), 1.64 (s, 3H, 3xH-6' Adda), 1.58 – 1.47 (m, 3H, H-β Glu, H-γ

Glu, H-β Leu), 1.08 (d, $J$ = 6.8 Hz, 3H, 3xH-2' Adda), 1.04 (d, $J$ = 6.7 Hz, 3H, 3xH-8' Adda),

0.97 (d, $J$ = 6.6 Hz, 3H, 3xH-δ Leu), 0.93 (d, $J$ = 7.4 Hz, 3H, CH$_3$ Ala), 0.88 (d, $J$ = 6.6 Hz, 3H,

3xH-δ Leu), 0.72 (d, $J$ = 7.1 Hz, 3H, CH$_3$ MeAsp); HRMS (ESI-TOF) m/z: [$M$+H]$^+$ Calcd for C$_{58}$H$_{73}$D$_5$N$_7$O$_{12}$Se 1149.5182; Found 1149.5175.

**[NMeSecPh$^7$]-Microcystin-LY(Prg) (23c).** The heptapeptide **22c** (29 mg, 20.3 μmol) was macrocyclized using pentafluorophenol (7.3 mg, 39.6 μmol) and DCC (5.1 mg, 24.8 μmol) according to GP7. The crude product was purified by semi-preparative RP-HPLC (gradient: 50-80% B in 30 min, $t_R$ = 20.6 min) and the macrocyclic peptide **23c** was obtained as a white amorphous solid (8 mg, 33%). $^1$H NMR (600 MHz, CD$_3$OD, 300 K) $\delta$ 8.83 (d, $J$ = 9.6 Hz, 1H, NH Tyr(Prg)), 8.19 (d, $J$ = 8.9 Hz, 1H, NH MeAsp), 8.00 (d, $J$ = 6.5 Hz, 1H, NH Glu), 7.52 (dd, $J$ = 8.0, 1.4 Hz, 2H, Ar), 7.36 – 7.28 (m, 3H, Ar), 7.26 (t, $J$ = 7.5 Hz, 2H, Ar), 7.22 – 7.16 (m, 4H, 3xH-Ar, NH Adda), 7.12 (d, $J$ = 8.4 Hz, 1H, NH Ala), 7.09 (d, $J$ = 8.6 Hz, 2H, Ar), 6.84 (d, $J$ = 8.8 Hz, 2H, Ar), 6.34 (d, $J$ = 15.5 Hz, 1H, H-5 Adda), 5.50 (d, $J$ = 9.9 Hz, 1H, H-7 Adda), 5.39 (dd, $J$ = 15.5, 8.7 Hz, 1H, H-4 Adda), 4.70 – 4.65 (m, 1H, H-3 Adda), 4.64 (d, $J$ = 2.4 Hz, 2H, -OCH$_2$-), 4.51 (dd, $J$ = 8.9, 3.0 Hz, 1H, H-α MeAsp), 4.49 – 4.41 (m, 2H, H-α Ala, H-α Tyr(Prg)), 4.25 (dd, $J$ = 9.2, 5.6 Hz, 1H, H-α Glu), 4.15 (ddd, $J$ = 11.2, 6.5, 3.9 Hz, 1H, H-α Leu), 4.06 (dd, $J$ = 9.8, 4.8 Hz, 1H, H-α NMeSecPh), 3.75 – 3.65 (m, 2H, 2xH-β NMeSecPh), 3.41 (dd, $J$ = 14.1, 3.3 Hz, 1H, H-β Tyr(Prg)), 3.30 – 3.26 (m, 1H, H-9 Adda), 3.26 (s, 3H,-OCH$_3$), 3.21 (s, 3H, -NCH$_3$), 2.91 (t, $J$ = 2.4 Hz, 1H, -C≡CH), 2.87 (qd, $J$ = 7.2, 3.0 Hz, 1H, H-β MeAsp), 2.84 (dd, $J$ = 14.0, 4.8 Hz, 1H, H-10 Adda), 2.70 (dd, $J$ = 14.0, 7.3 Hz, 1H, H-10 Adda), 2.66 – 2.59 (m, 2H, H-2 Adda, H-8 Adda), 2.49 (dd, $J$ = 14.1, 12.0 Hz, 1H, H-β Tyr(Prg)), 2.18 – 2.12 (m, 1H, H-γ Glu), 1.90 – 1.84 (m, 1H, H-β Glu), 1.84 – 1.74 (m, 2H, H-β Leu, H-γ Leu), 1.64 (s, 3H, 3xH-6' Adda), 1.59 – 1.54 (m, 1H, H-γ Glu), 1.52 – 1.43 (m, 2H, H-β Glu, H-β Leu), 1.09 (d, $J$ = 6.9 Hz, 3H, 3xH-2' Adda), 1.04 (d, $J$ = 6.7 Hz, 3H, 3xH-8' Adda), 0.97 (d, $J$ = 4.7 Hz, 3H, 3xH-δ Leu), 0.96 (d, $J$ = 5.5 Hz, 3H, CH$_3$ Ala), 0.88 (d, $J$ = 6.5 Hz, 3H, 3xH-δ Leu), 0.77 (d, $J$ = 7.2 Hz, 3H, CH$_3$ MeAsp); $^{13}$C NMR (151

38

MHz, CD$_3$OD, 300 K): $\delta$ = 178.3 (C=O), 176.41 (C=O), 176.38 (C=O), 175.80 (C=O), 175.77 (C=O), 175.3 (C=O), 174.9 (C=O), 171.64 (C=O), 171.54 (C=O), 158.0 (-$\underline{C}$-O-CH$_2$-), 140.5 (C Ar), 139.4 (C-5 Adda), 137.7 (C-7 Adda), 133.6 (C-6 Adda), 133.4 (2xC Ar), 131.7 (C Ar), 131.1 (2xC Ar Tyr(Prg)), 130.9 (C Ar), 130.5 (2xC Ar), 129.2 (2xC Ar), 128.5 (C Ar), 127.1 (2xC Ar), 125.8 (C-4 Adda), 116.0 (2xC Ar Tyr(Prg)),  88.4 (C-9 Adda), 79.8 (-$\underline{C}$≡CH), 76.8 (-C≡$\underline{C}$H), 67.5 (C-$\alpha$ NMeSecPh), 58.6 (-OCH$_3$), 56.5 (-OCH$_2$-), 56.0 (C-3 Adda), 55.31, 55.28, 55.19 (m, 3C, C-$\alpha$ Leu, C-$\alpha$ MeAsp, C-$\alpha$ Tyr(Prg)), 53.2 (C-$\alpha$ Glu), 49.7 (C-$\alpha$ Ala), 46.0 (C-2 Adda), 40.9 (-NCH$_3$), 40.7 (C-$\beta$ Leu), 40.4 (C-$\beta$ MeAsp), 39.0 (C-10 Adda), 37.7 (C-8 Adda), 37.3 (C-$\beta$ Tyr(Prg)), 32.8 (C-$\gamma$ Glu), 29.4 (C-$\beta$ Glu),  26.4 (C-$\beta$ NMeSecPh), 25.8 (C-$\gamma$ Leu), 23.6 (CH$_3$ Leu), 21.2 (CH$_3$ Leu), 17.3 (CH$_3$ Ala), 16.5 (C-8' Adda), 16.4 (C-2' Adda), 15.2 (CH$_3$ MeAsp), 12.9 (C-6' Adda); HRMS (ESI-Orbitrap) m/z: [$M$+H]$^+$ Calcd for C$_{61}$H$_{80}$N$_7$O$_{13}$Se 1198.49738; Found 1198. 49957.

## Acknowledgments

## Associated Content

**Supporting Information.** $^1H$ and $^{13}C$ spectra of synthesized compounds, LC-MS chromatograms of compounds **1a**, **1b**, **1c,** and bioassay data. The Supporting Information is available of free charge on the ACS Publications website at DOI:10.1021/acs.joc.xxxxxxx.

# References

(1)   Chorus, I.; Bartram, J. *Toxic Cyanobacteria in Water: A guide to their public health consequences, monitoring and management*; F & FN Spon: London, 1999.

(2)   (a) Michalak, A. M.; Anderson, E. J.; Beletsky, D.; Boland, S.; Bosch, N. S.; Bridgeman, T. B.; Chaffin, J. D.; Cho, K.; Confesor, R.; Daloğlu, I.; DePinto, J. V.; Evans, M. A.; Fahnenstiel, G. L.; He, L.; Ho, J. C.; Jenkins, L.; Johengen, T. H.; Kuo, K. C.; LaPorte, E.; Liu, X.; McWilliams, M. R.; Moore, M. R.; Posselt, D. J.; Richards, R. P.; Scavia, D.; Steiner, A. L.; Verhamme, E.; Wright, D. M.; Zagorski, M. A. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 6448-6452; (b) Pelley, J. *ACS Cent. Sci.* **2016**, *2*, 270-273.

(3)   (a) Qu, M.; Lefebvre, D. D.; Wang, Y.; Qu, Y.; Zhu, D.; Ren, W. *Science* **2014**, *346*, 175-176; (b) Paerl, H. W.; Gardner, W. S.; McCarthy, M. J.; Peierls, B. L.; Wilhelm, S. W. *Science* **2014**, *346*, 175-175.

(4)   Shoemaker, J. A.; Tettenhorst, D. R.; Delacruz, A. *Determination of microcystins and nodularin in drinking water by solid phase extraction and liquid chromatography/tandem mass spectrometry (LC/MS/MS)*; Shoemaker, J. A.; Tettenhorst, D. R.; Delacruz, A., Ed.; National Exposure Research Laboratory, Office of Research and Development: Cincinnati, Ohio 45268, 2015.

(5)   Francis, G. *Nature* **1878**, *18*, 11-12.

(6)   (a) Konst, H.; McKercher, P. D.; Gorham, P. R.; Robertson, A.; Howell, J. *Can. J. Comp. Med. Vet. Sci.* **1965**, *29*, 221-228; (b) Rinehart, K. L.; Harada, K.; Namikoshi, M.; Chen, C.; Harvis, C. A.; Munro, M. H. G.; Blunt, J. W.; Mulligan, P. E.; Beasley, V. R.; Dahlem, A.

M.; Carmichael, W. W. *J. Am. Chem. Soc.* **1988**, *110*, 8557-8558; (c) Pearson, L. A.; Dittmann, E.; Mazmouz, R.; Ongley, S. E.; D'Agostino, P. M.; Neilan, B. A. *Harmful Algae* **2016**, *54*, 98-111.

(7)   (a) Craig, M.; Luu, H. A.; McCready, T. L.; Holmes, C. F. B.; Williams, D.; Andersen, R. J. *Biochem. Cell Biol.* **1996**, *74*, 569-578; (b) Zemskov, I.; Kropp, H. M.; Wittmann, V. *Chem. Eur. J.* **2016**, *22*, 10990-10997.

(8)   (a) Campos, A.; Vasconcelos, V. *Int. J. Mol. Sci.* **2010**, *11*, 268-287; (b) Puddick, J.; Prinsep, M. R.; Wood, S. A.; Kaufononga, S. A. F.; Cary, S. C.; Hamilton, D. P. *Mar. Drugs* **2014**, *12*, 5372-5395.

(9)   (a) Clave, G.; Ronco, C.; Boutal, H.; Kreich, N.; Volland, H.; Franck, X.; Romieu, A.; Renard, P. Y. *Org. Biomol. Chem.* **2010**, *8*, 676-690; (b) Tappan, E.; Chamberlin, A. R. *Chem. Biol.* **2008**, *15*, 167-174; (c) Webster, K. L.; Maude, A. B.; O'Donnell, M. E.; Mehrotra, A. P.; Gani, D. *J. Chem. Soc., Perkin Trans. 1* **2001**, 1673-1695; (d) P. Mehrotra, A.; L. Webster, K.; Gani, D. *J. Chem. Soc., Perkin Trans. 1* **1997**, 2495-2512; (e) Taylor, C.; Quinn, R. J.; Alewood, P. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 2107-2112; (f) Taylor, C.; Quinn, R. J.; Suganuma, M.; Fujiki, H. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 2113-2116; (g) Fontanillo, M.; Zemskov, I.; Häfner, M.; Uhrig, U.; Salvi, F.; Simon, B.; Wittmann, V.; Köhn, M. *Angew. Chem.* **2016**, *128*, 14191-14195.

(10)  Humphrey, J. M.; Aggen, J. B.; Chamberlin, A. R. *J. Am. Chem. Soc.* **1996**, *118*, 11759-11770.

(11)  Aggen, J. B.; Humphrey, J. M.; Gauss, C.-M.; Huang, H.-B.; Nairn, A. C.; Chamberlin, A. R. *Bioorg. Med. Chem.* **1999**, *7*, 543-564.

(12)  (a) Böttcher, T.; Pitscheider, M.; Sieber, S. A. *Angew. Chem Int. Ed.* **2010**, *49*, 2680-2698; (b) Shreder, K. R.; Liu, Y.; Nomanhboy, T.; Fuller, S. R.; Wong, M. S.; Gai, W. Z.; Wu, J.; Leventhal, P. S.; Lill, J. R.; Corral, S. *Bioconjugate Chem.* **2004**, *15*, 790-798.

(13)  (a) Dawson, J. F.; Holmes, C. F. B. *Front. Biosci.* **1999**, D646-D658; (b) Goldberg, J.; Huang, H.-b.; Kwon, Y.-g.; Greengard, P.; Nairn, A. C.; Kuriyan, J. *Nature* **1995**, *376*, 745-753.

(14)  Lauer, J. L.; Fields, C. G.; Fields, G. B. *Lett. Pept. Sci.* **1995**, *1*, 197-205.

(15)  Tillett, D.; Dittmann, E.; Erhard, M.; von Döhren, H.; Börner, T.; Neilan, B. A. *Chem. Biol.* **2000**, *7*, 753-764.

(16)  (a) Pearson, C.; Rinehart, K. L.; Sugano, M.; Costerison, J. R. *Org. Lett.* **2000**, *2*, 2901-2903; (b) J. Cundy, D.; C. Donohue, A.; D. McCarthy, T. *J. Chem. Soc., Perkin Trans. 1* **1999**, 559-568; (c) Beatty, M. F.; Jennings-White, C.; Avery, M. A. *J. Chem. Soc., Perkin Trans. 1* **1992**, 1637-1641; (d) Deiters, A.; Schultz, P. G. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1521-1524; (e) Bauer, S. M.; Armstrong, R. W. *J. Am. Chem. Soc.* **1999**, *121*, 6355-6366; (f) Samy, R.; Kim, H. Y.; Brady, M.; Toogood, P. L. *J. Org. Chem.* **1999**, *64*, 2711-2728; (g) Valentekovich, R. J.; Schreiber, S. L. *J. Am. Chem. Soc.* **1995**, *117*, 9069-9070; (h) Panek, J. S.; Hu, T. *J. Org. Chem.* **1997**, *62*, 4914-4915.

(17)  Kokinaki, S.; Leondiadis, L.; Ferderigos, N. *Org. Lett.* **2005**, *7*, 1723-1724.

(18)  Riggs Costerison, J. *PhD Thesis, University of Illinois: Urbana* **2002**.

(19)  Okeley, N. M.; Zhu, Y.; van der Donk, W. A. *Org. Lett.* **2000**, *2*, 3603-3606.

(20)  Armstrong, A.; Geldart, S. P.; Jenner, C. R.; Scutt, J. N. *J. Org. Chem.* **2007**, *72*, 8091-8094.

(21)  Humphrey, J. M.; Bridges, R. J.; Hart, J. A.; Chamberlin, A. R. *J. Org. Chem.* **1994**, *59*, 2467-2472.

(22)  Bochenska, M.; Biernat, J. *Rocz. Chem.* **1972**, *46*, 1429-1433.

(23)  Carpino, L. A.; El-Faham, A. *J. Org. Chem.* **1994**, *59*, 695-698.

(24)  (a) Fischer, A.; Hoeger, S. J.; Stemmer, K.; Feurstein, D. J.; Knobeloch, D.; Nussler, A.; Dietrich, D. R. *Toxicol. Appl. Pharmacol.* **2010**, *245*, 9-20; (b) Heresztyn, T.; Nicholson, B. C. *Water Res.* **2001**, *35*, 3049-3056.

(25)  Dunn, P. J.; Haener, R.; Rapoport, H. *J. Org. Chem.* **1990**, *55*, 5017-5025.

(26)  Sakaguchi, K.; Yamamoto, M.; Kawamoto, T.; Yamada, T.; Shinada, T.; Shimamoto, K.; Ohfune, Y. *Tetrahedron Lett.* **2004**, *45*, 5869-5872.

(27)  dos Anjos, J. V.; Sinou, D.; de Melo, S. J.; Srivastava, R. M. *Synthesis* **2007**, 2647-2652.

(28)  Deiters, A.; Cropp, T. A.; Mukherji, M.; Chin, J. W.; Anderson, J. C.; Schultz, P. G. *J. Am. Chem. Soc.* **2003**, *125*, 11782-11783.

43